Anti-HLA-A2 antibodies and methods of using same

Humanized anti-HLA-A2 antibodies and CARs provide targeted immune modulation to address the limitations of current transplantation therapies, enhancing specificity and efficacy in preventing rejection and GVHD.

JP7578939B2Active Publication Date: 2024-11-07THE UNIV OF BRITISH COLUMBIA +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023075383
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-06-29
Filing Date
2023-05-01
Publication Date
2024-11-07
Estimated Expiration
2038-09-19

AI Technical Summary

Technical Problem

Current methods for modulating the immune response to HLA class I proteins in transplantation are limited, particularly in preventing acute and chronic rejection, with existing therapies risking temporary systemic immunosuppression and lacking specificity.

Method used

Development of humanized anti-HLA-A2 antibodies and chimeric antigen receptors (CARs) that specifically target HLA-A2, enabling the use of genetically engineered immune cells, such as regulatory T cells, to promote immune tolerance and prevent graft-versus-host disease and transplant rejection.

Benefits of technology

The humanized anti-HLA-A2 antibodies and CARs enhance the specificity and efficacy of immune cell therapies, reducing rejection and GVHD by promoting targeted immune modulation without systemic immunosuppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578939000057
    Figure 0007578939000057
  • Figure 0007578939000058
    Figure 0007578939000058
  • Figure 0007578939000059
    Figure 0007578939000059
Patent Text Reader

Abstract

To provide a method for modulating an immune response to HLA Class I protein, which is a critical target for immune recognition, in transplantation.SOLUTION: The present invention provides humanized anti-HLA-A2 antibodies, capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the CAR specifically binds to HLA-A2.SELECTED DRAWING: Figure 9-1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 560,574, filed September 19, 2017, and U.S. Provisional Patent Application No. 62 / 692,386, filed June 29, 2018, which are incorporated herein by reference in their entireties.

[0002] In some aspects, the present invention relates to HLA-A2 binding molecules, particularly humanized anti-HLA-A2 antibodies. The present invention further relates to recombinant receptors comprising the antibodies, including chimeric antigen receptors (CARs) comprising the antibodies. The present disclosure further relates to genetically engineered cells expressing the receptors and antibodies and their use in cell therapy. [Background technology]

[0003] Class I HLA antigens are polymorphic proteins expressed on all nucleated cells and are important targets of immune recognition in transplantation. Indeed, the development of HLA class I-specific T cells and / or antibodies is a major risk factor for acute and chronic allograft rejection, and the presence of preformed anti-donor HLA class I antibodies can lead to hyperacute rejection (Konvalinka et al., 2015). Therefore, finding a way to modulate the immune response to HLA class I proteins would be a major breakthrough in transplantation.

[0004] Classical HLA class I molecules are polymorphic and encoded by many different alleles that evolved in response to evolutionary pressures from infection. There are three loci encoding classical HLA class I proteins: the A, B, and C loci. Within the HLA-A locus, the HLA-A2 allele family is the largest and most diverse, with at least 31 distinct HLA-A2 alleles known to exist in humans. Interestingly, unlike many other HLA allele families, HLA-A2 is frequently present across all ethnicities, occurring in 50% of Caucasians and 35% of African Americans (Ellis et al., 2000). Most HLA-A2 alleles differ by only one to nine amino acids, with the majority of polymorphism concentrated around the peptide-binding groove (Hilton et al., 2013). HLA-A2 alleles are subgrouped into two major branches derived via interallelic gene conversion events, A*0201 or A*0205 (Ellis et al., 2000).

[0005] Adoptive immunotherapy with regulatory T (Treg) cells, a method for regulating unwanted immunity against HLA proteins and other antigens that cause transplant rejection, is a promising treatment for allograft rejection and graft-versus-host disease (GVHD). The use of polyclonal Treg cell transfer in preventing GVHD after allogeneic hematopoietic stem cell transplantation (HSCT) has been reported (Brunstein et al., 2011; Di Ianni et al., 2011; Trzonkowski et al., 2009). Treg cell transfer has also been reported in maintaining c-peptide levels in type 1 diabetes (Bluestone et al., 2015; Marek-Trzonkowska et al., 2012). Notably, there may be a risk of temporary systemic immunosuppression associated with the use of polyclonal Treg cells for such cell therapy (Brunstein et al., 2013).

[0006] Data from animal studies indicate that the use of antigen-specific cells can significantly improve the efficacy and specificity of Treg cell-based cell therapy. For example, in models of autoimmunity, antigen-specific Treg cells are superior to polyclonal Treg cells in alleviating disease. Treg cells isolated from pancreatic lymph nodes or pulsed with pancreatic islet antigens are significantly superior to polyclonal Treg cells in preventing or curing type 1 diabetes (Green et al., 2002; Masteller et al., 2005; Tang et al., 2004; Tarbell et al., 2007; Tarbell et al., 2004), and Treg cells expressing autoantigen-specific transgenic T cell receptors (TCRs) are superior to polyclonal Treg cells in suppressing central nervous system inflammation in a model of experimental autoimmune encephalomyelitis (EAE) (Stephens et al., 2009). Similarly, alloantigen-specific Treg cells (enriched by in vitro alloantigen-stimulated expansion or genetically engineered to express TCR transgenes) are more effective than polyclonal Treg cells in preventing rejection of organ and tissue transplants (Golshayan et al., 2007; Joffre et al., 2008; Nishimura et al., 2004; Sanchez-Fueyo et al., 2006; Tsang et al., 2008). There is some evidence that alloantigen-expanded Treg cells effectively prevent GVHD (Trenado et al., 2006), and that in vivo induction of antigen-specific Treg cells promotes hematopoietic allograft acceptance without GVHD (Verginis et al., 2008). Humanized mouse models have shown similar results: alloantigen-expanded human Treg cells are more potent suppressors of skin graft rejection than polyclonal Treg cells ( Putnam et al., 2013 ; Sagoo et al., 2011 ).

[0007] An alternative approach to overexpressing transgenic TCRs or antigen-stimulated proliferation to enrich for antigen-specific T cells is the use of chimeric antigen receptors (CARs). In cell-based adoptive immunotherapy, immune cells isolated from a patient can be modified to express synthetic proteins that enable the cells to perform a new therapeutic function after subsequent return to the patient. An example of such a synthetic protein is a CAR. An example of a currently used CAR is a fusion of an extracellular recognition domain (e.g., an antigen-binding domain), a transmembrane domain, and one or more intracellular signaling domains. Upon antigen engagement, the intracellular signaling portion of the CAR can initiate an activation-related response in the immune cell. For example, T cells can be engineered to express an extracellular single-chain antibody (scFv) antigen-binding domain fused to an intracellular signaling domain (Gill and June, 2015; June et al., 2015). In particular, Treg cells expressing CARs specific for model antigens have been reported ( Blat et al., 2014 ; Elinav et al., 2009 ; Elinav et al., 2008 ; Fransson et al., 2012 ; Hombach et al., 2009 ; Boardman et al., 2016 ; MacDonald et al., 2016 ; Noyan et al., 2016 ). Summary of the Invention

[0008] Embodiments of the present disclosure include anti-HLA-A2 antibodies. Also provided are chimeric antigen receptors (CARs) comprising an extracellular domain comprising any of the anti-HLA-A2 antibodies of the present disclosure. Also provided are nucleic acids encoding the anti-HLA-A2 antibodies and CARs of the present disclosure, expression vectors comprising the same, and host cells comprising the expression vectors. Embodiments of the present disclosure also include humanized anti-HLA-A2 antibodies. Also provided are chimeric antigen receptors (CARs) comprising an extracellular domain comprising any of the humanized anti-HLA-A2 antibodies of the present disclosure. Also provided are nucleic acids encoding the humanized anti-HLA-A2 antibodies and CARs of the present disclosure, expression vectors comprising the same, and host cells comprising the expression vectors. Also provided are immune cells, e.g., immune regulatory cells, comprising the CARs and / or expression vectors of the present disclosure, compositions and pharmaceutical compositions comprising the immune cells, kits of parts comprising the immune cells and / or reagents for generating the immune cells (e.g., nucleic acids or vectors encoding the anti-HLA-A antibodies or CARs of the present disclosure), and methods for generating the immune cells. Also provided are methods of using the anti-HLA-A2 antibodies, CARs, immune cells, and pharmaceutical compositions of the present disclosure. For example, the subject anti-HLA-A2 antibodies, CARs, immune cells (e.g., immunoregulatory cells), and pharmaceutical compositions find use in, for example, promoting immune tolerance in a subject, preventing or treating graft-versus-host disease (GVHD) in a subject, preventing or treating organ or tissue transplant rejection in a subject, etc.

[0009] In some embodiments, a humanized anti-HLA-A2 antibody is provided, which can constitute the antigen-binding domain of a chimeric antigen receptor (CAR), and the CAR can be expressed in a human cell (e.g., a human immune cell such as a human immunoregulatory cell) such that the CAR specifically binds to HLA-A2. In a specific aspect, the antibody competes for binding to HLA-A2 with an antibody comprising a heavy chain complementarity-determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity-determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity-determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity-determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity-determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity-determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190.

[0010] In a particular embodiment, a humanized anti-HLA-A2 antibody is provided, which competes for binding to HLA-A2 with an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190.

[0011] According to certain embodiments, the above-described humanized anti-HLA-A2 antibody binds to the same HLA-A2 epitope as an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190.

[0012] In some embodiments, a humanized anti-HLA-A2 antibody of the present disclosure has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, HLA-A*68, and any combination thereof, compared to a BB7.2 antibody. For example, in some embodiments, a humanized anti-HLA-A2 antibody of the present disclosure has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*25, HLA-A*29, HLA-A*30, and any combination thereof, compared to a BB7.2 antibody.

[0013] In certain embodiments, a humanized anti-HLA-A2 antibody of the present disclosure comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SYHIQ (SEQ ID NO: 1) and GYTFTSY (SEQ ID NO: 2).

[0014] According to certain embodiments, the humanized anti-HLA-A2 antibodies of the present disclosure are YPGDGS (SEQ ID NO: 4) and WIYPGDGSTX. 10 YX 12 X 13 KFX 16 and a heavy chain variable region comprising an amino acid sequence selected from the group consisting of X, X, XG (SEQ ID NO: 10), 10 is Q or K, and X 12 is N or S, and X 13 is E or Q, and X16 is K or Q. The antibody may, for example, comprise a heavy chain variable region comprising an amino acid sequence selected from the group consisting of WIYPGDGSTQYNEKFKG (SEQ ID NO: 3) and YPGDGS (SEQ ID NO: 4). Also, by way of example, the antibody may, for example, comprise a heavy chain variable region comprising the amino acid sequence WIYPGDGSTKYSQKFQG (SEQ ID NO: 5). In certain embodiments, the humanized antibody of the present disclosure comprises a heavy chain variable region comprising the amino acid sequence EGTYYAMDY (SEQ ID NO: 6).

[0015] In some embodiments, a humanized anti-HLA-A2 antibody of the present disclosure comprises a light chain variable region comprising the amino acid sequence RSSQSIVHSNGNTYLE (SEQ ID NO: 7). In particular aspects, a humanized antibody of the present disclosure comprises a light chain variable region comprising the amino acid sequence KVSNRFS (SEQ ID NO: 8). According to some embodiments, a humanized antibody of the present disclosure comprises a light chain variable region comprising the amino acid sequence FQGSHVPRT (SEQ ID NO: 9).

[0016] In certain embodiments, the humanized anti-HLA-A2 antibodies of the present disclosure comprise: QVQLVQSGAEVKKPGASVKVSCKAS (SEQ ID NO: 11) and QVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 12) The heavy chain variable region comprises a framework region 1 (VH FR1) comprising an amino acid sequence selected from the group consisting of:

[0017] According to certain embodiments, the humanized anti-HLA-A2 antibodies of the present disclosure comprise a heavy chain variable region comprising framework region 2 (VH FR2), wherein framework region 2 comprises: WVRQAPGQX 9 LEWMGX 15 (SEQ ID NO: 13), WVRQAPGQX 9 LEWMGX 15 WI (SEQ ID NO: 17), HIQWVRQAPGQX 12 LEWMGX 18 WI (SEQ ID NO: 21), and HIQWVRQAPGQX 12 LEWMGX 18 (SEQ ID NO: 25) and comprising an amino acid sequence selected from the group consisting of: In SEQ ID NO: 13, X 9 is R or G, and X 15 is I or absent, In SEQ ID NO: 17, X 9 is R or G, and X 15 is I or absent, In SEQ ID NO: 21, X 12 is R or G, and X 18 is I or absent, In SEQ ID NO: 25, X 12 is R or G, and X 18 is I or non-existent.

[0018] In some embodiments, a humanized anti-HLA-A2 antibody of the present disclosure comprises a heavy chain variable region comprising framework region 3 (VH FR3), wherein framework region 3 comprises: X 1 VTX 4 TX 6 DTSX 10 STAYMX 16 LSX 19 LRSX 23 DX 25 AVYYCAR (SEQ ID NO: 29), TX 2 YX 4 X 5 KFX 8 GX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 AVYYCAR (SEQ ID NO: 35), TQYNEKFKGX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX34 AVYYCAR (SEQ ID NO: 36), and TKYSQKFQGX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 AVYYCAR (SEQ ID NO: 37) and comprising an amino acid sequence selected from the group consisting of: In SEQ ID NO: 29, X 1 is R or absent, and X 4 is I or M, and X 6 is R or A, and X 10 is A, T or I, and X 16 is E or L, and X 19 is S or R, and X 23 is E or D, and X 25 is T or M, In SEQ ID NO: 35, X 2 is Q or K, and X 4 is N or S, and X 5 is E or Q, and X 8 is K or Q, and X 10 is R or absent, and X 13 is I or M, and X 15 is R or A, and X 19 is A, T or I, and X 25 is E or L, and X 28 is S or R, and X 32 is E or D, and X 34 is T or M, In SEQ ID NO: 36, X 10 is R or absent, and X 13 is I or M, and X 15 is R or A, and X 19 is A, T or I, and X 25 is E or L, and X 28 is S or R, and X 32 is E or D, and X 34 is T or M, In SEQ ID NO: 37, X 10is R or absent, and X 13 is I or M, and X 15 is R or A, and X 19 is A, T or I, and X 25 is E or L, and X 28 is S or R, and X 32 is E or D, and X 34 is T or M.

[0019] In certain aspects, the humanized anti-HLA-A2 antibodies of the present disclosure comprise a heavy chain variable region comprising framework region 4 (VH FR4) comprising the amino acid sequence WGQGTTVTVSS (SEQ ID NO: 44). According to certain embodiments, the humanized anti-HLA-A2 antibodies of the present disclosure comprise a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-66.

[0020] According to certain embodiments, the humanized anti-HLA-A2 antibody of the present disclosure has the amino acid sequence DX 2 VMTQX 7 PLSX 11 X 12 VTX 15 GQPASISX 23 a light chain variable region comprising framework region 1 (VL FR1) comprising (SEQ ID NO: 46), 2 is V or I, and X 7 is S or T, and X 11 is L or S, and X 12 is P or S, and X 15 is L or P, and X 23 is C or F.

[0021] In some embodiments, the humanized anti-HLA-A2 antibody of the present disclosure has the amino acid sequence WX 2 X 3 QX 5 PGQX 9 PX 11 X 12 a light chain variable region comprising framework region 2 (VL FR2) comprising X 2 is F or Y, and X 3 is Q or L, and X 5is R or K, and X 9 is S or P, and X 11 is R or Q, and X 12 is R or L.

[0022] In certain embodiments, the humanized anti-HLA-A2 antibody of the present disclosure has the amino acid sequence GVPDRFSGSGX 11 a light chain variable region comprising framework region 3 (VL FR3) comprising: GTDFTLKISRVEAEDVGVYYC (SEQ ID NO: 56); 11 is S or A. According to certain embodiments, the humanized anti-HLA-A2 antibodies of the present disclosure comprise a light chain variable region comprising framework region 4 (VL FR4) comprising the amino acid sequence FGGGTKVEIK (SEQ ID NO: 59). In some embodiments, the humanized anti-HLA-A2 antibodies of the present disclosure comprise a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 67-71. In some embodiments, the humanized anti-HLA-A2 antibody of the present disclosure is an antibody fragment selected from the group consisting of a whole antibody, a single-chain antibody, a dimeric single-chain antibody, an Fv, an scFv, a Fab, an F(ab)'2, a defucosylated antibody, a bispecific antibody, a diabody, a triabody, a tetrabody, a unibody, a domain antibody, and a nanobody, or an antibody mimetic selected from the group consisting of an affibody, an alphabody, an armadillo repeat protein-based scaffold, a knottin, a Kunitz domain peptide, an affilin, an affitin, an adnectin, an atrimer, an evasin, a DARPin, an anticalin, an avimer, a fynomer, a versabody, or a duocalin.

[0023] According to certain embodiments, the humanized anti-HLA-A2 antibody of the present disclosure is an scFv. For example, the humanized anti-HLA-A2 antibody of the present disclosure may be an scFv comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 72 to 91.

[0024] In some embodiments, the above-described humanized anti-HLA-A2 antibodies are provided, which are capable of constituting the antigen-binding domain of a chimeric antigen receptor (CAR), and the CAR is capable of being expressed in an immune cell (e.g., a regulatory T cell (Treg)) such that the CAR specifically binds to HLA-A2. In particular aspects, the above-described humanized anti-HLA-A2 antibodies are provided, which are capable of constituting the antigen-binding domain of a chimeric antigen receptor (CAR), and the CAR is capable of being expressed in an immune cell (e.g., a regulatory T cell (Treg)) such that the immune cell is activated by HLA-A2.

[0025] In certain embodiments, nucleic acids encoding any of the above-described humanized anti-HLA-A2 antibodies are provided. Expression vectors and gene therapy vectors containing the nucleic acids are also provided. Host cells containing the expression vectors or gene therapy vectors are also provided.

[0026] Embodiments of the present disclosure further include chimeric antigen receptors (CARs). For example, a CAR is provided that includes (i) an extracellular domain comprising any of the above-described humanized anti-HLA-A2 antibodies, (ii) a transmembrane domain, and (iii) a cytoplasmic domain comprising an intracellular signaling domain, and the CAR can be expressed in an immune cell so that the CAR specifically binds to HLA-A2. Compared to a CAR comprising the BB7.2 antibody, the CAR may have reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, HLA-A*68, and any combination thereof. For example, in some embodiments, the CAR has reduced reactivity to at least one HLA-A subtype selected from one or more of HLA-A*25, HLA-A*29, HLA-A*30, and any combination thereof, compared to a CAR comprising the BB7.2 antibody. The CAR of the present disclosure may be capable of being expressed in immune cells (e.g., regulatory T cells (Tregs)) such that the immune cells are activated by HLA-A2. The CAR of the present disclosure may comprise a hinge region. In certain aspects, the hinge region comprises the stalk region of CD8a.

[0027] A CAR of the present disclosure may comprise a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, T cell receptor alpha chain, T cell receptor beta chain, T cell receptor gamma chain, T cell receptor delta chain, CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154, and any combination thereof. In some embodiments, the transmembrane domain comprises the transmembrane domain of CD28.

[0028] According to certain embodiments, a CAR of the present disclosure comprises an intracellular signaling domain comprising a functional signaling domain of a protein selected from the group consisting of CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, FcR gamma, FcR alpha, FcR epsilon, CD5, CD22, CD79a, CD79b, and CD66d, and any combination thereof. In some embodiments, the intracellular signaling domain comprises a functional signaling domain of CD3 zeta. In certain aspects, the intracellular signaling domain further comprises a costimulatory domain. The costimulatory domain specifically binds to OX40, CD27, CD28, lymphocyte function-associated antigen-1 (LFA-1) (CD11a / CD18), TNFR1 (CD120a / TNFRSF1A), TNFR2 (CD120b / TNFRSF1B), CTLA-4 (CD152), CD95, ICOS (CD278), 4-1BB (CD137), CD2, CD30, CD40, PD-1, CD7, LIGHT, NKG2C, B7-H3, ICAM-1, and CD83. In certain embodiments, the costimulatory domain may comprise a functional signaling domain of a protein selected from the group consisting of CD28, IL2ra (CD25), IL6Ra (CD126), IL-7Ra (CD127), IL-13RA1, IL-13RA2, IL-33R (IL1RL1), IL-10RA, IL-10RB, IL-4R, IL-5R (CSF2RB), ARHR, BAFF receptor, IL-21R, TGFbR1, TGFbR2, TGFbR3, common gamma chain, and any combination thereof. According to certain embodiments, the costimulatory domain comprises a functional signaling domain of a protein selected from CD28 and 4-1BB. For example, the costimulatory domain may comprise a functional signaling domain of CD28.

[0029] Also provided are engineered immune cells comprising any of the CARs of the present disclosure. In some embodiments, the engineered immune cells are regulatory T cells (Tregs).

[0030] The present disclosure provides nucleic acids encoding any of the CARs of the present disclosure. Expression vectors comprising the nucleic acids are also provided, as are immune cells (e.g., regulatory T cells (Tregs)) comprising the expression vectors.

[0031] Compositions (e.g., pharmaceutical compositions) are also provided. In certain aspects, a plurality of modified immune cells of the present disclosure or pharmaceutical compositions comprising immune cells are provided. Kits of parts are also provided. In some embodiments, the kit of parts comprises, in a first part, an immune cell of the present disclosure and, in a second part, another therapeutic agent, such as, for example, an immunosuppressant. In some embodiments, the kit of parts comprises one or more reagents for producing a cell of the present disclosure (e.g., a nucleic acid or expression vector encoding an anti-HLA-A antibody or CAR of the present disclosure). Methods of producing modified immune cells of the present disclosure are also provided. In some embodiments, the method comprises transducing an immune cell with an expression vector of the present disclosure, thereby generating the modified immune cell.

[0032] Methods of using the antibodies, CARs, immune cells, engineered immune cells, and pharmaceutical compositions of the present disclosure are also provided. In certain aspects, methods of promoting immune tolerance in a subject are provided, the methods comprising administering to the subject a pharmaceutical composition of the present disclosure, e.g., an engineered immune cell or a pharmaceutical composition comprising a plurality of immune cells of the present disclosure. In some embodiments, the immune tolerance is tolerance to a transplanted organ or tissue. According to certain embodiments, methods of preventing or treating graft-versus-host disease (GVHD) in a subject are provided, the methods comprising administering to the subject a pharmaceutical composition of the present disclosure, e.g., an engineered immune cell or a pharmaceutical composition comprising a plurality of immune cells of the present disclosure. In certain aspects, the subject is undergoing or has undergone a hematopoietic stem cell transplant. Methods of preventing or treating organ or tissue transplant rejection in a subject are also provided, the methods comprising administering to the subject a pharmaceutical composition of the present disclosure, e.g., an engineered immune cell or a pharmaceutical composition comprising a plurality of immune cells of the present disclosure. In some embodiments, the subject is further receiving an immunosuppressant. According to certain embodiments, there is provided a method of preventing or treating organ or tissue transplant rejection or graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject a combination of immune cells of the present disclosure and at least one immunosuppressant to induce immune tolerance. In any of the methods using the antibodies, CARs, immune cells, modified immune cells, and pharmaceutical compositions of the present disclosure, the subject may be a human. [Brief explanation of the drawings]

[0033] [Figure 1] Construction of humanized anti-HLA-A2 CAR. Schematic of lentiviral constructs. Top: truncated NGFR control construct (no CAR); bottom: humanized anti-HLA-A2 CAR construct. "SP": signal peptide; "GS": glycine-serine linker; "TM": transmembrane region; "hs": humanized. [Figure 2-1]Cell surface expression and specificity of humanized anti-HLA-A2 CARs. 293T cells were transiently transfected with the indicated constructs, and 48 hours later, expression and antigen specificity were measured by flow cytometry staining with anti-ΔNGFR mAb and HLA-A2 tetramer. A and B show dot plots of constructs that retain or do not retain the ability to bind HLA-A2, respectively. Data are representative of two independent experiments. [Figure 2-2] Same as above. [Figure 3-1] Comparison of humanized anti-HLA-A2 CAR binding intensities. 293T cells were transfected with the indicated humanized anti-HLA-A2 CAR constructs and stained with the indicated dilutions of HLA-A2 tetramer. A, B, and C show graphs showing the geometric mean fluorescence intensity of HLA-A2 tetramer binding in gated ΔNGFR+ cells by constructs grouped according to light chain usage. [Figure 3-2] Same as above. [Figure 4-1] Expression and specificity of humanized anti-HLA-A2 CAR on Tregs. CD4+CD25hiCD127lo Tregs were activated and transduced with the indicated lentiviruses one day later, followed by expansion. Seven days after activation, ΔNGFR-expressing cells were selected by magnetic bead-based separation. Transduction efficiency and HLA-A2 binding were measured by flow cytometry before and after separation of ΔNGFR cells (A, B, C, and D). Numbers represent the percentage of ΔNGFR+ tetramer+ cells. Data are representative of independent experiments. (E) Summary data for the percent of A*02:01-tetramer binding or mean fluorescence intensity. [Figure 4-2] Same as above. [Figure 4-3] Same as above. [Figure 4-4] Same as above. [Figure 4-5] Same as above. [Figure 5-1]HLA-A2 CAR-mediated Treg activation. CD4+CD25hiCD127lo Tregs were activated, transduced with the indicated lentivirus, and then expanded. After 7 days, Tregs were rested overnight with 100 U / mL IL-2 and then stimulated or unstimulated by co-culture with anti-CD3 / 28-loaded CD64-K562 cells (TCR) or HLA-A2-K562 cells (CAR) at a 2:1 ratio (Tregs:K562 cells). After 24 hours, expression of CD69, CD154, CTLA-4, and LAP was measured by flow cytometry on live CD4+ cells. (A & B) Representative histograms and (C & D) average data from two independent experiments are shown. (E) ΔNGFR control / CAR Tregs were co-cultured with HLA-A2-expressing K562 cells at a 2:1 ratio (Tregs:K562 cells). After 16 hours, expression of CD69, CD71, CTLA-4, and LAP was measured by flow cytometry. (F) Positivity and fold increase over baseline (without K562) expression of CD69 and CD71. Positivity and fold increase over baseline (without K562) expression of CTLA-4 and LAP. Data are n = 2-4 for each construct from at least two independent experiments. One-way ANOVA with Holm-Sidak post-test comparing all constructs to mA2-CAR Tregs. Mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 5-2] Same as above. [Figure 5-3] Same as above. [Figure 5-4] Same as above. [Figure 5-5] Same as above. [Figure 5-6] Same as above. [Figure 6-1]Measurement of cross-reactivity of humanized anti-HLA-A2 CARs with common HLA-A and HLA-B allelic variants. (A) Schematic of the experimental setup and gating strategy for the FlowPRT cell assay. ΔNGFR Tregs expressing the indicated humanized CARs were incubated with Flow Panel Reactive Single Antigen beads and fixable viability dye for 30 minutes at room temperature. Samples were then washed, fixed, and analyzed by flow cytometry. (B) Binding of each m / hA2-CAR Treg to HLA-A*02:01-coated beads compared to binding of the ΔNGFR Treg control. (C & D) Correlation between mean HLA-A*02:01 binding measured by FlowPRT cell assay and either (C) HLA-A*02:01-tetramer MFI assessed by flow cytometry or (D) the increase in the percentage of CD69+ cells 16 hours after co-culture with HLA-A*02:01 relative to negative control HLA-A*24:01 K562 cells. Data in E, F, G, and H show percent binding relative to control Tregs expressing only truncated NGFR, normalized to the number of HLA-negative beads collected by the cytometer. Data points above the gray shaded area (E, F & G) or the horizontal dotted line (H) represent greater than two standard deviations from the mean of the bead-only control and are therefore statistically significant (p < 0.05). Data are the average of three independent experiments. (I) ΔNGFR or m / hA2-CAR Tregs were co-cultured with the indicated K562 cells transduced to express selected HLA-A alleles. After 16 hours, expression of CD69, CD71, LAP, and CTLA-4 was measured on live CD4+ T cells. n=2-6 from at least two independent experiments. Statistical significance determined by one-way ANOVA and Holm-Sidak post-test compared to mA2-CAR. Mean ± SEM, **p<0.01. [Figure 6-2] Same as above. [Figure 6-3] Same as above. [Figure 6-4] Same as above. [Figure 6-5] Same as above. [Figure 6-6] Same as above. [Figure 6-7] Same as above. [Figure 7-1] Tregs expressing a humanized HLA-A2 CAR potently suppress T cell proliferation stimulated by HLA-A2+ dendritic cells. (A) Schematic of the experimental setup. Mature HLA-A2+ dendritic cells were used to stimulate Cell Proliferation Dye (CPD)-e450-labeled HLA-A2neg CD4+ "responder" T cells. CPD-e660-labeled Tregs were either untransduced or transduced with a control lentivirus encoding ΔNGFR, or humanized A2 CAR-expressing Tregs. (B, C, D & E) The indicated ratios of cells were cocultured for 6 days, after which proliferation of CPD-e450-labeled responder CD4+ T cells was measured by flow cytometry. B shows a representative dot plot, while C, D, and E show graphical data for multiple cell ratios. C, D, and E show average data from n = 3–7 from at least three independent experiments. Statistics were performed using two-way ANOVA with Holm-Sidak post-test versus ΔNGFR Treg controls. *p<0.05, mean±SEM. [Figure 7-2] Same as above. [Figure 7-3] Same as above. [Figure 8-1]Tregs expressing a humanized HLA-A2 CAR potently suppress xenograft-versus-host disease. Irradiated NSG mice were injected with PBS (n=3), 8x106 HLA-A2+ PBMCs alone (n=5), or 4x106 H1k2 CAR-expressing Tregs (n=6). Blood human cell engraftment was monitored every 7 days. (A) Survival curves and (B) percent weight change relative to the start of the experiment. (C) Percentage of total human CD45-expressing mononuclear cells (viable singlets) in the blood. (D) Gating strategy distinguishing between total human CD45+ and CAR Treg (hCD45+hCD4+HLA-A2-) cell engraftment. (E) In vivo cell engraftment after adoptive transfer in a xenograft-versus-host disease mouse model, expressed as absolute numbers of PBMCs and CAR Tregs engrafted per μL of blood. The number of PBMCs was calculated as hCD45+ minus the number of total CAR Tregs gated at D. [Figure 8-2] Same as above. [Figure 9-1] Expression of the m / hA2 CAR confers rapid and sustained homing of Tregs to HLA-A2:01+ skin allografts. Tregs were co-transduced with a luciferase-encoding lentivirus and either a control HER2-CAR, mA2-CAR, or hA2-CAR (H1k2). The dual-transduced cells were sorted by FACS and expanded for 5 days before being injected into NSG mice previously transplanted with juxtaposed skin grafts from both NSG and NSG-HLA-A*02:01 transgenic mice. (A) Schematic of the experimental setup. (B) Representative luciferase imaging of skin grafts 72 hours (left) or 21 days (right) after Treg injection. Luciferase luminescence was quantified using the average number of photons / second / cm² / steradian and plotted as the ratio of HLA-A*02:01-NSG skin grafts to NSG skin grafts (C) 72 h after Treg injection or (D) over time. n = 2–3 per group from three independent experiments, mean ± standard error. Repeated measures ANOVA with Bonferroni correction. [Figure 9-2] Same as above. [Figure 10-1]Flow cytometry tracking of m / hA2 CAR Tregs with rapid and sustained homing to HLA-A2:01+ skin allografts. Tregs were co-transduced with lentivirus containing luciferase and either HER2-CAR, mA2-CAR, or hA2-CAR constructs, expanded, and injected into transplanted NSG mice, as shown in Figure 9. (A) Pre-gating of flow cytometry plots was based on cells from the spleen of control HER2-CAR. (B) hCD4 / hCD8 flow cytometry profiles of the indicated constructs. As in (A), plots were pre-gated on FvD-hCD45+. (C) Flow cytometry plots showing staining of m / hA2-CAR Tregs in the spleen and draining lymph nodes at the experimental endpoint, n=1 per group, from one independent experiment. *p<0.05. [Figure 10-2] Same as above. [Figure 11-1]hA2-CAR-Tregs reduce human skin allograft rejection. NSG mice were transplanted with HLA-A*02:01+ human skin and injected 3 weeks later with either PBS (n=3); HLA-A*02:01neg PBMCs alone (n=4), or autologous H1k2 CAR Tregs at a 2:1 ratio (n=6). PBMC / hA2-CAR Tregs were derived from two individual donors tested in one experiment. (A) Body weight was monitored three times weekly, and (B) the percentage of human CD45+ cells in the blood (left) and spleen (right) was measured at the experimental endpoint. (C) Cumulative histological scores of transplanted skin sections were determined by H&E staining. (D) Transplanted skin grafts were immunostained at the experimental endpoint to quantify involucrin expression and the percentage of Ki-67+ cells within the epidermis. (E) mRNA expression of the indicated genes in transplanted skin sections was measured by qRT-PCR. (F) Transplanted skin grafts were immunostained at the experimental endpoint to quantify the percentage of FOXP3+ cells within human CD45+ cells. (G) Transplanted skin grafts, intestine, lung, and liver sections were immunostained at the experimental endpoint to show the percentage of FOXP3+ cells within human CD45+ cells in each tissue. Each data point represents one mouse. Box plots show the mean ± range. Statistical significance determined by a two-tailed Mann-Whitney test comparing PBMCs to H1k2. *p<0.05. [Figure 11-2] Same as above. [Figure 11-3] Same as above. [Figure 12] Flow cytometry tracking of hA2 CAR Tregs in the blood in a human skin transplantation model. NSG mice were transplanted with human HLA-A*02+ skin and injected with cells as shown in Figure 11. (A) Gating strategy to identify overall human CD45+ (PBMC) and CAR Treg (hCD45+hCD4+NGFR+) cell engraftment. (B) Absolute number of PBMCs per μL of blood and CAR Treg engraftment over time. The number of PBMCs was calculated by subtracting the total number of CAR Tregs from the hCD45+ gated in (A). [Figure 13-1]Activation of hA2 CAR Tregs with artificial antigen-presenting cells. ΔNGFR control / CAR Tregs were co-cultured for 16 hours either without stimulation or with a 2:1 (Treg:K562) ratio of CD64-expressing K562 cells bound to anti-CD3 and anti-CD28 monoclonal antibodies (TCR stimulation). (A) Example of gating strategy. (B) Expression of CD69, CD71, CTLA-4, and LAP was measured by flow cytometry (left). The fold increase of each activation marker relative to baseline (no stimulation) was calculated (right). Data are n=2-4 for each construct from at least two independent experiments. Mean ± standard error. One-way ANOVA and Holm-Sidak multiple comparison test comparing all constructs to mA2-CAR Tregs. *p<0.05, **p<0.01, ****p<0.0001. [Figure 13-2] Same as above. DETAILED DESCRIPTION OF THE INVENTION

[0034] I. General Techniques

[0035] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are fully explained in such references as "Molecular Cloning: A Laboratory Manual," 2nd Edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, (ed.), 1984); "Animal Cell Culture" (R.I. Freshney, (ed.), 1987); "Methods in Enzymology" (Academic Press, Inc.); "Current Protocols in Molecular Biology" (F.M.Ausubel et al., (eds.), 1987 and regularly updated); "PCR: The Polymerase Chain Reaction" (Mullis et al., (eds.), 1994); "A Practical Guide to Molecular Cloning" (Perbal Bernard V., 1988); "Phage Display: A Laboratory Manual" (Barbas et al., 2001).

[0036] It is to be understood that the invention is not limited to the particular embodiments described, as such may, of course, vary, and the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are described herein. One of ordinary skill in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below. All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. In the event that a stated definition conflicts with a document incorporated herein by reference, the stated definition shall control.

[0038] II. Definition

[0039] The terms "a" and "an" refer to one or to more than one of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0040] The term "about" when referring to a measurable value, such as an amount, time period, or the like, is meant to encompass variations of ±20%, or in some cases ±10%, or in some cases ±5%, or in some cases ±1%, or in some cases ±0.1% from the specified value, as such variations are reasonable in practicing the disclosed methods.

[0041] When a range of values ​​is provided, it is understood that each intervening value (to the tenth of the unit of the lower limit unless the context clearly dictates otherwise) between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0042] As used herein, the terms "HLA-A2" and "A2" refer to human leukocyte antigen (HLA) proteins, including cell surface proteins, encoded by the HLA-A*02 allele family at the HLA-A locus of the HLA gene complex, respectively. HLA proteins encompassed by the terms "HLA-A2" and "A2" include HLA proteins identified as belonging to the HLA-A*02 antigen type by serological testing or genotyping. Additional names for the HLA-A*02 antigen type include "HLA-A2," "HLA-A02," and "HLA-A*2." Different nomenclature systems have been developed to identify HLA proteins encoded by this allele family, including the HLA nomenclature system developed by the WHO Committee for Factors of the HLA System in 2010. The terms "HLA-A2" and "A2" refer to HLA proteins encoded by alleles designated according to this naming system beginning with "HLA-A*02:", including, but not limited to, designations beginning with "HLA-A*02:01", "HLA-A*02:02", "HLA-A*02:03", "HLA-A*02:04", "HLA-A*02:05", "HLA-A*02:06", "HLA-A*02:07", "HLA-A*02:08", "HLA-A*02:09", "HLA-A*02:10", and "HLA-A*02:11". In addition to the number following "HLA-A*02:", the allele designation may also include capital letters, including but not limited to capital "P" and "G" (e.g., HLA-A*02:01P or HLA-A*02:01:01G). An allele designation beginning with "HLA-A*02:" followed by 2, 3, or 4 additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics.The terms "HLA-A2" and "A2" also refer to HLA proteins identified by designations beginning with "HLA-A*02:" according to this naming system, including, but not limited to, the designations "HLA-A*02:01," "HLA-A*02:02," "HLA-A*02:03," "HLA-A*02:04," "HLA-A*02:05," "HLA-A*02:06," "HLA-A*02:07," "HLA-A*02:08," "HLA-A*02:09," "HLA-A*02:10," and "HLA-A*02:11."

[0043] As used herein, "HLA-A subtype" refers to the proteins encoded by alleles of the HLA-A gene.

[0044] As used herein, the term "HLA-A*03" refers to HLA proteins, including cell surface proteins, encoded by the HLA-A*03 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the term "HLA-A*03" include HLA proteins identified by serological testing or genotyping as belonging to the HLA-A*03 antigen type. Additional names for the HLA-A*03 antigen type include "HLA-A03" and "HLA-A3." The term "HLA-A*03" refers to HLA proteins encoded by alleles named according to the HLA nomenclature system developed in 2010 by the WHO Committee for Factors of the HLA System beginning with "HLA-A*03:", including, but not limited to, nomenclatures beginning with "HLA-A*03:01", "HLA-A*03:02", "HLA-A*03:04", "HLA-A*03:05", "HLA-A*03:06", "HLA-A*03:07", "HLA-A*03:08", "HLA-A*03:09", "HLA-A*03:10", and "HLA-A*03:12". In addition to the number following "HLA-A*03:", the allele designation may also include capital letters, including but not limited to capital "P" and "G" (e.g., HLA-A*03:01P or HLA-A*03:01:01G). An allele designation beginning with "HLA-A*03:" followed by 2, 3, or 4 additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics. The term "HLA-A*03" also refers to HLA proteins identified by a designation beginning with "HLA-A*03:" according to this naming system, including, but not limited to, "HLA-A*03:01," "HLA-A*03:02," "HLA-A*03:04," "HLA-A*03:05," "HLA-A*03:06," "HLA-A*03:07," "HLA-A*03:08," "HLA-A*03:09," "HLA-A*03:10," and "HLA-A*03:12," "P," and "G."

[0045] As used herein, the terms "HLA-A*25," "HLA-A25," and "A25" each refer to HLA proteins, including cell surface proteins, encoded by the HLA-A*25 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the terms "HLA-A*25," "HLA-A25," and "A25" include HLA proteins identified as belonging to the HLA-A*25 antigen type by serological testing or genotyping. Additional names for the HLA-A*25 antigen type include "HLA-A25." The terms "HLA-A*25," "HLA-A25," and "A25" refer to HLA proteins encoded by alleles named according to the HLA nomenclature system developed in 2010 by the WHO Committee for Factors of the HLA System, beginning with "HLA-A*25:," including, but not limited to, "HLA-A*25:01," "HLA-A*25:02," "HLA-A*25:03," "HLA-A*25:04," "HLA-A*25:05," "HLA-A*25:06," "HLA-A*25:07," "HLA-A*25:08," "HLA-A*25:09," "HLA-A*25:10," and "HLA-A*25:11." In addition to the number following "HLA-A*25:", the allele designation may also include capital letters, including but not limited to capital "P" and "G" (e.g., HLA-A*25:01P or HLA-A*25:01:01G). An allele designation beginning with "HLA-A*25:" followed by 2, 3, or 4 additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics.The terms "HLA-A*25," "HLA-A25," and "A25" also refer to HLA proteins identified by designations beginning with "HLA-A*25:" according to this naming system, including, but not limited to, the designations "HLA-A*25:01," "HLA-A*25:02," "HLA-A*25:03," "HLA-A*25:04," "HLA-A*25:05," "HLA-A*25:06," "HLA-A*25:07," "HLA-A*25:08," "HLA-A*25:09," "HLA-A*25:10," and "HLA-A*25:11."

[0046] As used herein, the terms "HLA-A*29," "HLA-A29," and "A29" each refer to HLA proteins, including cell surface proteins, encoded by the HLA-A*29 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the terms "HLA-A*29," "HLA-A29," and "A29" include HLA proteins identified as belonging to the HLA-A*29 antigen type by serological testing or genotyping. Additional names for the HLA-A*29 antigen type include "HLA-A29." The terms "HLA-A*29," "HLA-A29," and "A29" refer to HLA proteins encoded by alleles named according to the HLA nomenclature system developed in 2010 by the WHO Committee for Factors of the HLA System, beginning with "HLA-A*29:," including, but not limited to, "HLA-A*29:01," "HLA-A*29:02," "HLA-A*29:03," "HLA-A*29:04," "HLA-A*29:05," "HLA-A*29:06," "HLA-A*29:07," HLA-A*29:09," "HLA-A*29:10," and "HLA-A*29:11." In addition to the number following "HLA-A*29:", the allele designation may also include capital letters, including but not limited to capital "P" and "G" (e.g., HLA-A*29:02P or HLA-A*29:02:01G). An allele designation beginning with "HLA-A*29:" followed by 2, 3, or 4 additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics.The terms "HLA-A*29", "HLA-A29", and "A29" also refer to HLA proteins identified by designations beginning with "HLA-A*29:" according to this naming system, including, but not limited to, the designations "HLA-A*29:01", "HLA-A*29:02", "HLA-A*29:03", "HLA-A*29:04", "HLA-A*29:05", "HLA-A*29:06", "HLA-A*29:07", "HLA-A*29:09", "HLA-A*29:10", and "HLA-A*29:11".

[0047] As used herein, the terms "HLA-A*30," "HLA-A30," and "A30" each refer to HLA proteins, including cell surface proteins, encoded by the HLA-A*30 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the terms "HLA-A*30," "HLA-A30," and "A30" include HLA proteins identified as belonging to the HLA-A*30 antigen type by serological testing or genotyping. Additional names for the HLA-A*30 antigen type include "HLA-A30." The terms "HLA-A*30," "HLA-A30," and "A30" refer to HLA proteins encoded by alleles named according to the HLA nomenclature system developed in 2010 by the WHO Committee for Factors of the HLA System, beginning with "HLA-A*30:01," "HLA-A*30:02," "HLA-A*30:03," "HLA-A*30:04," "HLA-A*30:06," "HLA-A*30:07," "HLA-A*30:08," or "HLA-A*30:." In addition to the number following "HLA-A*30:", the allele designation may also include capital letters, including, but not limited to, capital "P" and "G" (e.g., HLA-A*30:01P, HLA-A*30:02P, HLA-A*30:04P, HLA-A*30:01:01G, HLA-A*30:02:01G, or HLA-A*30:04:01G). An allele designation beginning with "HLA-A*30:" followed by two, three, or four additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics.The terms "HLA-A*30", "HLA-A30" and "A30" also refer to HLA proteins identified by designations beginning with "HLA-A*30:" according to this naming system, including, but not limited to, the designations "HLA-A*30:01", "HLA-A*30:02", "HLA-A*30:03", "HLA-A*30:04", "HLA-A*30:06", "HLA-A*30:07", "HLA-A*30:08", "HLA-A*30:09", "HLA-A*30:10" and "HLA-A*30:11".

[0048] As used herein, the terms "HLA-A*31," "HLA-A31," and "A31" each refer to HLA proteins, including cell surface proteins, encoded by the HLA-A*31 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the terms "HLA-A*31," "HLA-A31," and "A31" include HLA proteins identified as belonging to the HLA-A*31 antigen type by serological testing or genotyping. Additional names for the HLA-A*31 antigen type include "HLA-A31." The terms "HLA-A*31," "HLA-A31," and "A31" refer to HLA proteins encoded by alleles named according to the HLA nomenclature system developed in 2010 by the WHO Committee for Factors of the HLA System, beginning with "HLA-A*31:," including, but not limited to, "HLA-A*31:01," "HLA-A*31:02," "HLA-A*31:03," "HLA-A*31:04," "HLA-A*31:05," "HLA-A*31:06," "HLA-A*31:07," "HLA-A*31:08," "HLA-A*31:09," "HLA-A*31:10," and "HLA-A*31:11." In addition to the number following "HLA-A*31:", the allele designation may also include capital letters, including but not limited to capital "P" and "G" (e.g., HLA-A*31:01P or HLA-A*31:01:02G). An allele designation beginning with "HLA-A*31:" followed by 2, 3, or 4 additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics.The terms "HLA-A*31", "HLA-A31", and "A31" also refer to HLA proteins identified by designations beginning with "HLA-A*31:" according to this naming system, including, but not limited to, the designations "HLA-A*31:01", "HLA-A*31:02", "HLA-A*31:03", "HLA-A*31:04", "HLA-A*31:05", "HLA-A*31:06", "HLA-A*31:07", "HLA-A*31:08", "HLA-A*31:09", "HLA-A*31:10", and "HLA-A*31:11".

[0049] As used herein, the terms "HLA-A*33," "HLA-A33," and "A33" each refer to HLA proteins, including cell surface proteins, encoded by the HLA-A*33 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the terms "HLA-A*33," "HLA-A33," and "A33" include HLA proteins identified as belonging to the HLA-A*33 antigen type by serological testing or genotyping. Additional names for the HLA-A*33 antigen type include "HLA-A33." The terms "HLA-A*33," "HLA-A33," and "A33" refer to HLA proteins encoded by alleles named according to the HLA nomenclature system developed in 2010 by the WHO Committee for Factors of the HLA System, beginning with "HLA-A*33:," including, but not limited to, "HLA-A*33:01," "HLA-A*33:03," "HLA-A*33:04," "HLA-A*33:05," "HLA-A*33:06," "HLA-A*33:07," "HLA-A*33:08," "HLA-A*33:09," "HLA-A*33:10," and "HLA-A*33:11." In addition to the number following "HLA-A*33:", the allele designation may also include capital letters, including but not limited to capital "P" and "G" (e.g., HLA-A*33:01P or HLA-A*33:01:01G). An allele designation beginning with "HLA-A*33:" followed by 2, 3, or 4 additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics.The terms "HLA-A*33", "HLA-A33", and "A33" also refer to HLA proteins identified by designations beginning with "HLA-A*33:" according to this naming system, including, but not limited to, the designations "HLA-A*33:01", "HLA-A*33:03", "HLA-A*33:04", "HLA-A*33:05", "HLA-A*33:06", "HLA-A*33:07", "HLA-A*33:08", "HLA-A*33:09", "HLA-A*33:10", and "HLA-A*33:11".

[0050] As used herein, the terms "HLA-A*36," "HLA-A36," and "A36" each refer to HLA proteins, including cell surface proteins, encoded by the HLA-A*36 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the terms "HLA-A*36," "HLA-A36," and "A36" include HLA proteins identified as belonging to the HLA-A*36 antigen type by serological testing or genotyping. Additional names for the HLA-A*36 antigen type include "HLA-A36." The terms "HLA-A*36," "HLA-A36," and "A36" refer to HLA proteins encoded by alleles named according to the HLA naming system developed in 2010 by the WHO Committee for Factors of the HLA System, which begins with "HLA-A*36:," including, but not limited to, "HLA-A*36:01," "HLA-A*36:02," "HLA-A*36:03," "HLA-A*36:04," and "HLA-A*36:05." In addition to the number following "HLA-A*36:," the allele name may also include capital letters, including, but not limited to, capital letters "P" and "G." An allele name beginning with "HLA-A*36:" followed by two, three, or four additional numbers may constitute a complete name or the beginning of a name. The allele name may be in italics. The terms "HLA-A*36," "HLA-A36," and "A36" also refer to HLA proteins identified by designations beginning with "HLA-A*36:" according to this naming system, including, but not limited to, the designations "HLA-A*36:01," "HLA-A*36:02," "HLA-A*36:03," "HLA-A*36:04," "HLA-A*36:05," and "HLA-A*36:06."

[0051] As used herein, the terms "HLA-A*68," "HLA-A68," and "A68" each refer to HLA proteins, including cell surface proteins, encoded by the HLA-A*68 allele family at the HLA-A locus of the HLA gene complex. HLA proteins encompassed by the terms "HLA-A*68," "HLA-A68," and "A68" include HLA proteins identified as belonging to the HLA-A*68 antigen type by serological testing or genotyping. Additional names for the HLA-A*68 antigen type include "HLA-A68." The terms "HLA-A*68," "HLA-A68," and "A68" refer to HLA proteins encoded by alleles named according to the HLA nomenclature system developed in 2010 by the WHO Committee for Factors of the HLA System, beginning with "HLA-A*68:," including, but not limited to, "HLA-A*68:01," "HLA-A*68:02," "HLA-A*68:03," "HLA-A*68:04," "HLA-A*68:05," "HLA-A*68:06," "HLA-A*68:07," "HLA-A*68:08," "HLA-A*68:09," and "HLA-A*68:10." In addition to the number following "HLA-A*68:", the allele designation may also include capital letters, including but not limited to capital "P" and "G" (e.g., HLA-A*68:01P, HLA-A*68:01:01G, or HLA-A*68:01:02G). An allele designation beginning with "HLA-A*68:" followed by 2, 3, or 4 additional numbers may constitute a complete designation or the beginning of a designation. The allele designation may be in italics.The terms "HLA-A*68", "HLA-A68", and "A68" also refer to HLA proteins identified by designations beginning with "HLA-A*68:" according to this naming system, including, but not limited to, the designations "HLA-A*68:01", "HLA-A*68:02", "HLA-A*68:03", "HLA-A*68:04", "HLA-A*68:05", "HLA-A*68:06", "HLA-A*68:07", "HLA-A*68:08", "HLA-A*68:09", and "HLA-A*68:10".

[0052] As used herein, certain HLA proteins may be referred to using the protein's nomenclature according to the HLA nomenclature system developed by the WHO Committee for Factors of the HLA System in 2010. For example, the term "HLA-A*02:01" as used herein refers to the HLA protein designated "HLA-A*02:01" according to this nomenclature system. Similarly, the terms "HLA-A*03:01", "HLA-A*25:01", "HLA-A*29:02", "HLA-A*30:01", "HLA-A*31:01", "HLA-A*33:01", "HLA-A*36:01", and "HLA-A*68:01" refer to the HLA proteins designated "HLA-A*03:01", "HLA-A*25:01", "HLA-A*29:02", "HLA-A*30:01", "HLA-A*31:01", "HLA-A*33:01", "HLA-A*36:01", and "HLA-A*68:01", respectively.

[0053] As used herein, the term "anti-HLA-A2 antibody" refers to an antibody that preferentially or specifically binds to HLA-A2.

[0054] As used herein, the term "BB7.2" refers to a murine hybridoma identified as ATCC deposit number HB-82. BB7.2 hybridoma cells secrete a murine monoclonal antibody of the IgG2b kappa isotype, characterized by Parham, P. et al. and Hilton et al. (Parham, P. et al., 1981; Hilton et al., 2013). The amino acid sequences of the six complementarity-determining regions (CDRs) of the monoclonal antibody secreted by BB7.2 are as follows: Heavy chain CDR1 (HCDR1): SYHIQ (SEQ ID NO: 183); Heavy chain CDR2 (HCDR2): WIYPGDGSTQYNEKFKG (SEQ ID NO: 185); Heavy chain CDR3 (HCDR3): EGTYYAMDY (SEQ ID NO: 187); Light chain CDR1 (LCDR1): RSSQSIVHSNGNTYLE (SEQ ID NO: 188); Light chain CDR2 (LCDR2): KVSNRFS (SEQ ID NO: 189); Light chain CDR3 (LCDR3): FQGSHVPRT (SEQ ID NO: 190).

[0055] As used herein, a "BB7.2 antibody" is an antibody having the VH (SEQ ID NO: 191) and VL (SEQ ID NO: 192) of the monoclonal antibody secreted by BB7.2. The BB7.2 antibody may be a whole antibody or a fragment thereof having the VH and VL of the monoclonal antibody secreted by BB7.2, such as an scFv having the VH and VL of the monoclonal antibody secreted by BB7.2.

[0056] The terms "antibody" and "immunoglobulin" include antibodies or immunoglobulins of any isotype, fragments of antibodies that retain specific binding to an antigen (including, but not limited to, Fab, Fab', F(ab')2, Fv, scFv, Fd, diabodies, single domain antibodies (sdAbs), linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments), chimeric antibodies, humanized antibodies, single-chain antibodies, and fusion proteins comprising the antigen-binding portion of an antibody and a non-antibody protein.

[0057] Antibodies may be polyclonal or monoclonal, multi-chain or single-chain, or may be intact immunoglobulins, derived from natural or recombinant sources. Antibodies may be tetramers of immunoglobulin molecules. The basic four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. In the case of IgG, the four-chain unit is generally approximately 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, and the two H chains are linked to each other by one or more disulfide bonds, depending on the H chain isotype. Each H and L chain also contains regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at its N-terminus, followed by three constant domains (CH) for the α and γ chains, and four CH domains for the μ and ε isotypes. Each L chain has a variable domain (VL) at its N-terminus followed by a constant domain (CL) at its other end. The VL aligns with the VH, which aligns with the first constant domain (CH1) of the heavy chain. Specific amino acid residues are thought to form an interface between the light and heavy chain variable domains. The pairing of a VH and a VL results in the formation of a single antigen-binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology, 8th ed., Daniel P. Stites, Abba I. Terr, and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, Connecticut, 1994, p. 71 and Chapter 6. Based on the amino acid sequence of their constant domains, L chains of vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda. Depending on the amino acid sequence of the constant domain of their heavy chain (CH), immunoglobulins can be assigned to different classes or isotypes. The five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, have heavy chains called α, δ, ε, γ, and μ, respectively.The gamma and alpha classes are further divided into subclasses based on relatively minor differences in CH sequence and function; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0058] The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of the antibody. The variable domain of the heavy chain is called "VH", VH The variable domain of the light chain is sometimes referred to as "VL," "H," or "H." VL These domains are generally the most variable parts of an antibody and contain the antigen-binding site.

[0059] The term "variable" refers to the fact that the sequences of certain segments of the variable domains vary significantly among antibodies. The V domain mediates antigen binding and defines the specificity of a particular antibody for its specific antigen. However, variability is not evenly distributed across the 110-130 amino acids of the variable domains. Instead, the V regions consist of relatively invariant stretches of 15-30 amino acids called framework regions (FRs), separated by shorter regions of extreme variability called "hypervariable regions," each 9-12 amino acids long. Naturally occurring heavy and light chain variable domains each have four FRs, adopting a primarily β-sheet configuration, connected by three hypervariable regions, which form loops that connect (and in some cases form part of) the β-sheet structure. The hypervariable regions of each chain are held together in close proximity by the FRs and, together with the hypervariable regions of the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD. (1991)).

[0060] An "intact" antibody is one that comprises an antigen-binding site and a CL and at least heavy chain constant domains, CH1, CH2, and CH3. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. In one embodiment, an intact antibody may have one or more effector functions.

[0061] The term "antibody fragment" refers to at least a portion of an intact antibody or a recombinant variant thereof, including the antigen-binding domain, e.g., the antigen-determining variable region, of the intact antibody, sufficient to confer recognition and specific binding of the antibody fragment to a target, such as an antigen. Examples of antibody fragments include Fab, Fab', F(ab'), Fv fragments, scFv fragments; diabodies; single-domain antibodies (sdAbs); linear antibodies (see U.S. Pat. No. 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10):1057-1062

[1995] ); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. In one embodiment, the antibody fragment comprises the antigen-binding site of the intact antibody and thus retains the ability to bind to an antigen. Fragments of anti-HLA-A2 antibodies also include portions of anti-HLA-A2 antibodies (and combinations of anti-HLA-A2 antibody portions (e.g., scFvs)) that can be used as targeting arms (directed against HLA-A2) in chimeric antigen receptors of CAR-modified immune cells. Such fragments are not necessarily proteolytic fragments, but rather portions of polypeptide sequences that can confer affinity for a target. Further included among anti-HLA-A2 antibody fragments are single domain antibodies (sdAbs) (see, e.g., Li et al., 2017; Jamnani et al., 2014). Such single domain antibodies can be used as targeting arms in the CAR-modified immune cells of the present invention.

[0062] Papain digestion of antibodies produces two identical antigen-binding fragments called "Fab" fragments and a residual "Fc" fragment, a designation reflecting their ability to crystallize readily. The Fab fragment consists of the entire L chain, along with the variable region domain (VH) of the H chain and the first constant domain (CH1) of one heavy chain. Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of antibodies produces a single large F(ab')2 fragment, which roughly corresponds to two disulfide-linked Fab fragments with bivalent antigen-binding activity and is still capable of cross-linking antigen. Fab' fragments differ from Fab fragments by the addition of several residues at the carboxy terminus of the CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH is the designation used herein for Fab', in which the cysteine ​​residue(s) in the constant domains bear a free thiol group. F(ab')2 antibody fragments were originally produced as pairs of Fab' fragments with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0063] The Fc fragment contains the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of an antibody are determined by the sequence of the Fc region, which is also the region recognized by Fc receptors (FcRs) found on certain types of cells.

[0064] An "Fv" is the minimum antibody fragment that contains a complete antigen-recognition and antigen-binding site. This fragment consists of a dimer of one heavy-chain variable domain and one light-chain variable domain in tight, non-covalent association. In single-chain Fv (scFv) species, one heavy-chain variable domain and one light-chain variable domain can be covalently linked by a flexible peptide linker, allowing the light and heavy chains to associate in a "dimeric" structure similar to that of a two-chain Fv species. The folding of these two domains generates six hypervariable loops (three loops each from the heavy and light chains) that contribute antigen-binding amino acid residues and confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific CDRs) has the ability to recognize and bind antigen, albeit with lower affinity than the entire binding site.

[0065] A "single-chain Fv," also abbreviated as "sFv" or "scFv," is an antibody fragment comprising a VH antibody domain and a VL antibody domain connected in a single polypeptide chain. The scFv polypeptide may further comprise a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding. Unless otherwise specified, as used herein, an scFv can have the VL and VH variable domains in either order, e.g., with respect to the N- and C-termini of the polypeptide, and can comprise either a VL-linker-VH or a VH-linker-VL. For a review of scFvs, see Pluckthun in The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Rosenburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994); Antibody Engineering, edited by Borrebaeck, Oxford University Press, New York (1995). In one embodiment, an scFv derived from an anti-HLA-A2 antibody can be used as the targeting arm of the CAR-modified immune cells disclosed herein.

[0066] The term "adnectin," also known as monobody, is well known in the art and refers to proteins designed to bind to antigens with high affinity and specificity. They belong to a class of molecules collectively called "antibody mimetics."

[0067] The term "alphabody" refers to a class of antibody mimetics called cell-permeable alphabodies, which consist of small 10 kDa proteins genetically engineered to bind to various antigens. Alphabodies are able to reach and bind to intracellular protein targets.

[0068] The term "affibody" is well known in the art and refers to an affinity protein based on a 58 amino acid residue protein domain derived from one of the IgG binding domains of Staphylococcus protein A.

[0069] The term "anticalin" is well known in the art and refers to antibody mimetic technology whose binding specificity is derived from lipocalin. Anticalins can also be formatted as dual targeting proteins called duocalins.

[0070] The term "armadillo repeat protein-based scaffold" refers to a type of antibody mimetic that corresponds to an artificial peptide-binding scaffold based on armadillo repeat proteins, which are characterized by an armadillo domain composed of tandem armadillo repeats of approximately 42 amino acids that mediate interactions with peptides or proteins.

[0071] The term "avimer" is well known in the art and refers to antibody mimetic technology. The term "DARPin" (Designed Ankyrin Repeat Protein) is well known in the art and refers to antibody mimetic DRP (designed repeat protein) technology that has been developed to exploit the binding capacity of non-antibody polypeptides.

[0072] The term "diabody" refers to small antibody fragments prepared by constructing scFv fragments with a short linker (approximately 5-10 residues) between the VH and VL domains such that intrachain, but not interchain, pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., a fragment with two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossover" scFv fragments in which the VH and VL domains of the two antibodies are present on different polypeptide chains. Diabodies are more fully described in, for example, EP 0404097; WO 93 / 11161; and Holliger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[0073] The term "evasin" is well known in the art and refers to a class of chemokine-binding proteins.

[0074] The term "antibody mimetics" is well known in the art and refers to proteins that belong to the class of antibody mimetics. They are attractive binding molecules because of their high thermostability and low immunogenicity.

[0075] The term "knottin" (also called inhibitor cystine knot) refers to an antibody mimetic that contains a protein structural motif that includes three disulfide bridges.

[0076] The term "Kunitz domain peptide" refers to a type of antibody mimetic, based on the active domain of a protein that inhibits the function of a protease.

[0077] The term "nanobody" is well known in the art and refers to antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally occurring heavy chain antibodies. These heavy chain antibodies contain a single variable domain (VHH) and two constant domains (CH2 and CH3).

[0078] The term "unibody" is well known in the art and refers to an antibody fragment that lacks the hinge region of an IgG4 antibody. The deletion of the hinge region results in a molecule that is essentially half the size of a conventional IgG4 antibody and has a univalent binding region rather than the bivalent binding region of an IgG4 antibody.

[0079] The term "versabodies" is well known in the art and refers to another antibody mimetic technology. They are small proteins of 3-5 kDa with more than 15% cysteines, forming a high disulfide density scaffold that replaces the hydrophobic core of typical proteins.

[0080] The term "flexible polypeptide linker" or "linker" as used in the context of scFvs refers to a peptide linker composed of amino acids such as glycine and / or serine residues, used alone or in combination, to connect the variable heavy and variable light chain regions. In one embodiment, the flexible polypeptide linker is a Gly / Ser linker, having the amino acid sequence (Gly-Gly-Gly-Ser) n where n is a positive integer greater than or equal to 1. For example, n=1, n=2, n=3, n=4, n=5, n=6, n=7, n=8, n=9, and n=10. In another embodiment, the flexible polypeptide linker is a Gly / Ser linker and has the amino acid sequence (Gly-Gly-Gly-Gly-Ser) n where n is a positive integer equal to or greater than 1. For example, n=1, n=2, n=3, n=4, n=5, n=6, n=7, n=8, n=9, and n=10. In one embodiment, the flexible polypeptide linker includes, but is not limited to, (Gly4Ser)4 or (Gly4Ser)3. In another embodiment, the linker includes multiple repeats of (Gly2Ser), (GlySer), or (Gly3Ser). Also included within the scope of the present invention are linkers described in WO2012 / 138475, which is incorporated herein by reference.

[0081] The term "heavy chain" refers to the larger of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations, and usually determines the class to which the antibody belongs.

[0082] The term "light chain" refers to the smaller of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations. Kappa (K) light chain and lambda (λ) light chain refer to the two major antibody light chain isotypes.

[0083] The terms "hypervariable region," "HVR," or "HV," as used herein, refer to the regions of an antibody variable domain that are hypervariable in sequence and / or form structurally defined loops. Antibodies generally contain six hypervariable regions: three in the VH (H1, H2, and H3) and three in the VL (L1, L2, and L3). Many hypervariable region delineations are in use and are encompassed herein. The Kabat complementarity-determining regions (CDRs), based on sequence diversity, are the most commonly used (Kabat et al., 1991). Chothia instead refers to the location of the structural loops (Chothia et al., 1987). The end of the Chothia CDR-H1 loop, when numbered using the Kabat numbering system, varies between H32 and H34, depending on the length of the loop (this is because the Kabat numbering scheme places insertions at H35A and H35B. If neither 35A nor 35B are present, the loop ends at 32. If only 35A is present, the loop ends at 33. If both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions are intermediate between the Kabat CDRs and the Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software. The "contact" hypervariable regions are based on analysis of the available complex crystal structures. The residues in each of these hypervariable regions are listed below. The residues in each of these hypervariable regions are listed below. [Table 1]

[0084] The terms "hypervariable region" and "complementarity determining region" and their respective abbreviations (HVR, HV, CDR) are used interchangeably herein. Furthermore, the following pairs of terms are also used interchangeably herein: "VH CDR1" and "HCDR1"; "VH CDR2" and "HCDR2"; "VH CDR3" and "HCDR3"; "VL CDR1" and "LCDR1"; "VL CDR2" and "LCDR2"; and "VL CDR3" and "LCDR3".

[0085] The hypervariable regions may comprise "extended hypervariable regions" as follows: 24-36 or 24-34 (L1), 46-56 or 50-56 (L2) and 89-97 (L3) for VL, and 26-35B (H1), 50-65, 47-65 or 49-65 (H2) and 93-102, 94-102 or 95-102 (H3) for VH. The variable domain residues are numbered according to Kabat et al. (Kabat et al., 1991) for each of these definitions.

[0086] "Framework" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.

[0087] The terms "Kabat-like variable domain residue numbering" or "Kabat-like amino acid position numbering" and variations thereof refer to the numbering system used for the heavy or light chain variable domains of the antibody compilations in Kabat et al. (Kabat et al., 1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, the FRs or CDRs of the variable domain. For example, a heavy chain variable domain may contain a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and inserted residues after heavy chain FR residue 82 (e.g., residues 82a, 82b, and 82c according to Kabat). The Kabat numbering of residues can be determined for a given antibody by alignment of the antibody sequence with a "standard" Kabat-numbered sequence at the regions of homology.

[0088] When referring to residues within the variable domain (residues 1-107 of the light chain and residues 1-13 of the heavy chain), the Kabat numbering system is generally used (e.g., Kabat et al., 1991). When referring to residues within the constant region of an immunoglobulin heavy chain, the "EU numbering system" or "EU index" is generally used (e.g., the EU index reported in Kabat et al., supra). "Kabat-like EU index" refers to the residue numbering of the human IgG1 EU antibody. Unless otherwise specified herein, references to residue numbers in the variable domain of an antibody refer to residue numbering according to the Kabat numbering system.

[0089] The term "specifically binds" refers to a ligand (e.g., a humanized anti-HLA-A2 antibody) that recognizes and binds to its cognate binding partner (e.g., HLA-A2) protein present in a sample, but the ligand does not substantially recognize or bind to other molecules in the sample. Non-specific binding is defined as binding to a specific target molecule (e.g., a humanized anti-HLA-A2 antibody). -7 Binding with an affinity less than M, e.g., 10 -6 M, 10 -5 M, 10 -4 It refers to binding with an affinity such as M.

[0090] An antibody that "specifically binds" to an antigen or epitope of interest is one that binds to the antigen or epitope with sufficient affinity that it is clearly distinct from nonspecific interactions. Specific binding can be measured, for example, by determining the binding of a molecule compared to the binding of a control molecule.

[0091] The term "recombinant antibody" refers to an antibody produced using recombinant DNA technology, such as, for example, an antibody expressed in a bacteriophage or yeast expression system. This term should also be construed to mean an antibody produced by synthesis of a DNA molecule encoding the antibody, which DNA molecule expresses an antibody protein or an amino acid sequence specifying the antibody, where the DNA or amino acid sequence has been obtained using recombinant DNA or amino acid sequence technology available and well known in the art.

[0092] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies (i.e., the individual antibodies comprising the population are identical except for possible minor naturally occurring mutations). Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies useful in the present invention can be prepared by the hybridoma methodology first described by Kohler et al., Nature, 256:495 (1975), or can be made using recombinant DNA methods in bacterial, eukaryotic, or plant cells (see, e.g., U.S. Pat. No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in, for example, Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991).

[0093] The term "antigen" refers to a molecule that elicits an immune response. This immune response can involve either antibody production or activation of specific immunocompetent cells, or both. Those skilled in the art will appreciate that any macromolecule, including virtually any protein or peptide, can function as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. Those skilled in the art will appreciate that any DNA containing a nucleotide sequence or partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an "antigen," as that term is used herein. Those skilled in the art will also appreciate that an antigen need not necessarily be encoded solely by the full-length nucleotide sequence of a gene. As will be readily apparent, the present invention includes, but is not limited to, the use of partial nucleotide sequences of multiple genes, and these nucleotide sequences may be arranged in various combinations to encode a polypeptide that elicits a desired immune response. Furthermore, those skilled in the art will appreciate that an antigen need not be encoded by a "gene" at all. As will be readily apparent, an antigen can be generated or synthesized from a biological sample, can be derived from a biological sample, or can be a macromolecule other than a polypeptide. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells or fluids containing other biological components.

[0094] As used herein, the term "affinity" refers to the equilibrium constant for the reversible binding of two agents, expressed as the dissociation constant (Kd). The affinity may be at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, at least 70-fold, at least 80-fold, at least 90-fold, at least 100-fold, or at least 1000-fold or greater than the affinity of the antibody for an unrelated amino acid sequence. The affinity of the antibody for the target protein may be, for example, from about 100 nanomolar (nM) to about 0.1 nM, from about 100 nM to about 1 picomolar (pM), or from about 100 nM to about 1 femtomolar (fM), or greater. As used herein, the term "avidity" refers to the resistance of a complex of two or more agents to dissociation after dilution. The terms "immunoreactive," "preferentially bind," and "specifically bind" are used interchangeably herein with respect to antibodies and fragments thereof. As such terms are used herein, the anti-HLA-A2 antibodies and fragments thereof of the present invention, including humanized anti-HLA-A2 antibodies, specifically bind to HLA-A2.

[0095] The term "binding" refers to a direct association between two molecules, for example, by covalent, electrostatic, hydrophobic, and ionic and / or hydrogen bonding interactions, including interactions such as salt bridges and water bridges. -7 Binding with an affinity less than M, e.g., 10 -6 M, 10 -5 M, 10 -4 It refers to binding with an affinity such as M.

[0096] As used herein, the term "reactivity" refers to the ability of an antibody to react with (i.e., bind to) a molecule (e.g., specifically bind to) a molecule. A first antibody is "less reactive" with a molecule (e.g., an HLA molecule) than a second antibody if the first antibody exhibits reduced binding to the molecule compared to the second antibody. Approaches are known for easily comparing the reactivity of first and second antibodies with one or more specific HLA molecules. One example of an approach is provided in the Examples section herein, employing FlowPRA® Single Antigen Beads (One Lambda) to test antibodies for their ability to react with (or bind to) specific HLA molecules. Such flow cytometry approaches are suitable for high-throughput antibody reactivity analysis.

[0097] As used herein, the term "hinge region" refers to a flexible polypeptide connector region (also referred to herein as a "hinge" or "spacer") that provides structural flexibility and spacing between adjacent polypeptide regions and can be composed of natural or synthetic polypeptides. The hinge region may affect the potency of immune cells expressing CARs (see, e.g., Watanabe et al., 2016). The "hinge region" from an immunoglobulin (e.g., IgG1) is generally defined as extending from Glu216 to Pro230 of human IgG1 (Burton, 1985, Molec. Immunol., 22:161-206). Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by placing the first and last cysteine ​​residues that form inter-heavy chain disulfide (SS) bonds in the same positions. Hinge regions can be naturally occurring or non-naturally occurring, including, but not limited to, the modified hinge regions described in U.S. Patent No. 5,677,425. The hinge region can comprise a complete hinge region derived from an antibody of a different class or subclass than that of the CH1 domain. The term "hinge region" can also include regions derived from CD8 and other receptors, which serve similar functions in providing flexibility and spacing to adjacent regions.

[0098] As used herein, the term "immune cells" generally includes blood cells (white blood cells) derived from hematopoietic stem cells (HSCs) produced in the bone marrow. "Immune cells" include, for example, lymphocytes (T cells, B cells, natural killer (NK) cells) and bone marrow-derived cells (neutrophils, eosinophils, basophils, monocytes, macrophages, dendritic cells).

[0099] "T cells" are T helper cells (CD4 + cells), CD8 + T cells (e.g. cytotoxic CD8 + T cells, regulatory CD8 + It includes all types of immune cells that express CD3, including T cells, regulatory T cells (Tregs), gamma delta T cells, and double-negative T cells.

[0100] "Cytotoxic cells" are cytotoxic CD8 + These cells include T cells, natural killer (NK) cells and neutrophils, and are capable of mediating the cytotoxic response.

[0101] As used herein, the term "regulatory immune cells" refers to immune cells that act in a "regulatory" manner to suppress immune system activation, thereby maintaining immune system homeostasis and tolerance to self-antigens. "Regulatory immune cells" may also affect non-immune cells that result in clinical improvement, such as promoting tissue repair or regeneration. Regulatory immune cells include regulatory T cells, CD4 + Regulatory T cells, CD8 + These include regulatory T cells, regulatory γδ T cells, regulatory DN T cells, regulatory B cells, regulatory NK cells, regulatory macrophages and regulatory dendritic cells.

[0102] As used herein and in the claims, the terms "regulatory T lymphocytes," "regulatory T cells," "T regulatory cells," "Treg cells," or "Treg" are synonymous and are intended to have their standard definitions as used in the art. Treg cells are a specialized subpopulation of T cells that act "regulatory" to suppress immune system activation, thereby maintaining immune system homeostasis and tolerance to self-antigens. Tregs are sometimes called suppressor T cells. Treg cells are often, but not always, characterized by expression of the forkhead family transcription factor Foxp3 (forkhead box p3). They may also express CD4 or CD8 surface proteins. They usually also express CD25. As used herein and in the claims, unless otherwise specified, Tregs include "natural" Tregs that arise in the thymus, inducible / adaptive / peripheral Tregs that arise through a differentiation process outside the thymus (e.g., in tissues or secondary lymphoid organs, or in the laboratory under defined culture conditions), and Tregs created using recombinant DNA technology (e.g., by manipulating FOXP3 expression). Naturally occurring Treg cells (CD4+CD25+Foxp3+) develop like all other T cells in the thymus. In contrast, inducible / adaptive / peripheral Treg cells (including CD4+CD25+Foxp3+ Tregs, Tr1 cells, Th3 cells, and others) develop outside the thymus. One method for inducing Tregs is to expose T effector cells to IL-10 or TGF-β. T cells can also be converted into Treg cells by transfecting or transducing a mixed population of T cells with the Foxp3 gene. T cells that are forced to express Foxp3 adopt a Treg phenotype, and such recombinant Tregs are also defined herein as "Tregs."

[0103] As used herein, the term "immune effector cell" refers to a cell of the immune system in a form that is capable of initiating a specific immune response.

[0104] As used herein, the term "immune response" includes T cell-mediated and / or B cell-mediated immune responses. Exemplary immune responses include T cell responses, such as cytokine production and cellular cytotoxicity. Furthermore, the term immune response includes immune responses indirectly influenced by T cell activation, e.g., antibody production (humoral response), and activation of cytokine-responsive cells (e.g., macrophages). Immune cells involved in an immune response include lymphocytes, such as B cells and T cells (CD4+, CD8+, Th1 cells, and Th2 cells); antigen-presenting cells (e.g., professional antigen-presenting cells, such as dendritic cells, macrophages, B lymphocytes, and Langerhans cells, and non-professional antigen-presenting cells, such as keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes); natural killer cells; and myeloid cells, such as macrophages, eosinophils, mast cells, basophils, and granulocytes.

[0105] The term "rejection" refers to the failure of a transplanted organ or tissue to be accepted by the recipient's body. Rejection results from the recipient's immune system attacking the transplanted organ or tissue. Rejection can occur days to weeks after transplantation (acute) or months to years after transplantation (chronic).

[0106] As used herein, the term "graft-versus-host disease" or "GVHD" refers to a medical complication after receiving transplanted tissue from a genetically different individual. Immune cells in the donated tissue (graft) recognize the recipient (host) as foreign. The transplanted immune cells then attack the host's somatic cells. GVHD is commonly associated with stem cell transplants; however, the term includes GVHD resulting from other forms of tissue transplants. GVHD can also occur after blood transfusions.

[0107] As used herein, the term "immunological tolerance" or "immune tolerance" refers to a method implemented in a portion of treated subjects compared to untreated subjects, which results in: a) a reduction in the level of a specific immunological response (believed to be mediated, at least in part, by antigen-specific effector T lymphocytes, B lymphocytes, antibodies, or their equivalents); b) a delay in the initiation or progression of a specific immunological response; or c) a reduction in the risk of initiation or progression of a specific immunological response. "Specific" immunological tolerance or immune tolerance occurs when immunological tolerance or immune tolerance is preferentially induced to a particular antigen compared to other antigens.

[0108] As used herein, the term "post-transplant operational tolerance" refers to a clinical state in which stable graft function continues for at least one year in the absence of histological signs of rejection (including acute or chronic rejection) in the absence of any immunosuppressive drug treatment in an immunocompetent host that is able to respond to other challenges, including infection.

[0109] As used herein, the term "immune adaptation" refers to a state in a transplant recipient in which an organ or tissue transplant functions normally despite the presence in the recipient of antibodies specific to the organ or tissue transplant.

[0110] As used herein, the term "stem cells" generally includes pluripotent or multipotent stem cells, including, for example, embryonic stem cells (ES), mesenchymal stem cells (MSC), induced pluripotent stem cells (iPS), and committed progenitor cells (e.g., hematopoietic stem cells (HSC), bone marrow-derived cells).

[0111] As used herein, the terms "treatment," "treating," and the like refer to obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic in terms of partial or complete cure of a disease and / or side effects resulting from a disease. As used herein, "treatment" encompasses any treatment of a disease in a mammal, e.g., a human, and includes causing alleviation of the disease, i.e., causing regression of the disease and / or relief of one or more symptoms of the disease.

[0112] As used herein, the terms "prevention," "prevent," "preventing," and the like refer to providing prophylactic or protective treatment of a disease or condition. The effect may be prophylactic in that the disease or its symptoms are completely or partially prevented. As used herein, "prevention" encompasses any prophylactic effect against disease in a mammal, e.g., a human, including: (a) preventing the disease from occurring in a subject who may be predisposed to the disease but has not yet been diagnosed as having the disease; and (b) suppressing the disease, i.e., preventing its onset.

[0113] The terms "patient," "subject," "individual," "host," and the like are used interchangeably herein and refer to an animal or cells thereof, either in vitro or in situ, that can be subjected to the methods described herein. The terms "patient," "subject," "individual," "host," and the like are intended to include organisms (e.g., mammals) in which an immune response can be elicited. Examples of "patient," "subject," "individual," and "host" include murines (e.g., rats, mice), lagomorphs (e.g., rabbits), non-human primates, humans, dogs, cats, ungulates (e.g., horses, cows, sheep, pigs, goats), and the like, as well as transgenic species thereof. In certain non-limiting embodiments, the patient, subject, host, or individual is human.

[0114] The terms "effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a therapeutic agent, or a combined amount of multiple therapeutic agents, that can elicit the biological or medical response in a tissue, system, or subject that is desired by a researcher, veterinarian, physician, or other clinician. The term "therapeutically effective amount" includes an amount of a therapeutic agent that, when administered, is sufficient to prevent (or alleviate to some extent) the development of one or more of the signs or symptoms of the disorder or disease being treated. The therapeutically effective amount will vary depending on the therapeutic agent, the disease and its severity, and the age, weight, etc., of the subject being treated.

[0115] As used herein, the term "activated" refers to a state of T cells (e.g., regulatory T cells) that have been stimulated sufficiently to induce a detectable cellular response. Activation can also be associated with detectable effector function(s), such as cytokine production or suppressive activity. The term "activated" regulatory T cells refers, inter alia, to regulatory T cells that are capable of suppressing an immune response.

[0116] The term "chimeric antigen receptor" or "CAR" refers to a recombinant polypeptide construct comprising an extracellular domain comprising an antigen-binding domain, a transmembrane domain, and a cytoplasmic domain comprising an intracellular signaling domain. In one embodiment, a CAR optionally comprises a hinge. The term "chimeric receptor" or "chimeric antigen receptor" or "CAR" may refer to a polypeptide or a set of polypeptides (usually two in the simplest embodiments) that, particularly when present in an immune cell, provides the cell with specificity for a target ligand and intracellular signal generation. In some embodiments, the set of polypeptides are in close proximity to each other. In some embodiments, the chimeric receptor is a chimeric fusion protein comprising the set of polypeptides. In some embodiments, the set of polypeptides comprises a dimerization switch that allows the polypeptides to be coupled to each other (e.g., coupling a ligand-binding domain to an intracellular signaling domain) upon the presence of a dimerization molecule. In one embodiment, the chimeric receptor comprises an optional leader sequence at the amino-terminus (N-ter) of the chimeric receptor fusion protein. In one embodiment, the chimeric receptor further comprises a leader sequence at the N-terminus of the extracellular ligand-binding domain, wherein the leader sequence is optionally cleaved from the ligand-binding domain during cellular processing and localization of the chimeric receptor to the plasma membrane.

[0117] The term "signaling domain" refers to a functional portion of a protein that acts by transmitting information within the cell to regulate cellular activity through defined signaling pathways, either by generating second messengers or by functioning as an effector by responding to such messengers.

[0118] The term "autologous" refers to material originating from the same subject that is later reintroduced into the subject.

[0119] The term "allogeneic" refers to any material derived from a different subject of the same species as the subject into which the material is introduced. Two or more subjects are said to be allogeneic to each other when the genes at one or more loci are not identical. In some embodiments, allogeneic materials from subjects of the same species may not be sufficiently genetically similar, resulting in antigenic interaction. The term "allograft" refers to a graft derived from a different subject of the same species.

[0120] The term "xenogeneic" refers to any material derived from a subject of a different species. The term "xenograft" refers to a graft derived from a subject of a different species.

[0121] As used herein, "instructional material" includes publications, records, diagrams, or any other medium of expression that can be used to communicate the utility of the compositions and methods of the invention. The instructional material of the kits of the invention may, for example, be affixed to a container containing the nucleic acids, peptides, cells, and / or compositions of the invention, or may be shipped together with the container containing the nucleic acids, peptides, cells, and / or compositions. Alternatively, the instructional material may be shipped separately from the container, with the intention that the instructional material and the nucleic acids, peptides, cells, and / or compositions be used together by the recipient.

[0122] As used herein, a "modification" of an amino acid residue / position refers to a change in the primary amino acid sequence compared to the starting amino acid sequence, resulting from a change in the sequence containing the amino acid residue / position. For example, typical modifications include substitution of the residue (or at the position) with another amino acid (e.g., conservative or non-conservative substitution), insertion of one or more (generally fewer than five or three) amino acids adjacent to the residue / position, or deletion of the residue / position. An "amino acid substitution" or variant thereof refers to the substitution of an amino acid residue present in a given (starting) amino acid sequence with a different amino acid residue. Generally, and preferably, the modification results in a change in at least one physico-biochemical activity of the variant polypeptide compared to a polypeptide comprising the starting (or "wild-type") amino acid sequence. For example, in the case of an antibody, the altered physico-biochemical activity can be binding affinity, binding ability, and / or binding efficacy for a target molecule.

[0123] The term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies or antibody fragments of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in a CAR of the invention can be substituted with other amino acid residues from the same side chain family, and the modified CAR can be tested using the functional assays described herein.

[0124] The term "stimulation" refers to a primary response elicited by the binding of a stimulatory molecule (e.g., the TCR / CD3 complex) to its cognate ligand, thereby mediating a signal transduction event, such as, but not limited to, signal transduction through the TCR / CD3 complex. Stimulation can mediate changes in the expression of specific molecules, such as up- or down-regulation of cytokines and cell surface proteins, and / or rearrangements of cytoskeletal structure, etc.

[0125] The term "stimulatory molecule" refers to a molecule expressed by a T cell that provides a primary cytoplasmic signaling sequence(s) that regulates primary activation of the TCR complex in a stimulatory manner for at least some aspect of the T cell signaling pathway. In one embodiment, the primary signal is initiated, for example, by binding of the TCR / CD3 complex to a peptide-bound MHC molecule and leads to mediation of a T cell response, including, but not limited to, proliferation, activation, and differentiation. The primary cytoplasmic signaling sequence (also referred to as a "primary signaling domain") that acts in a stimulatory manner may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif (ITAM).

[0126] The term "antigen-presenting cell" or "APC" refers to immune system cells, such as accessory cells (e.g., B cells, dendritic cells, macrophages, Langerhans cells, etc.), that display antigens complexed with major histocompatibility complexes (MHC) on their surface for recognition by specific lymphocytes, such as T cells. T cells can recognize these complexes using their T cell receptors (TCRs). Antigen-presenting cells can process antigens for presentation with MHC. As used herein, the term "antigen-presenting cell" or "APC" encompasses situations in which an APC presents antigen and situations in which an APC does not present antigen. In some cases, an APC processes antigen and presents it to a T cell. In other instances, a T cell can recognize an APC in the absence of antigen presentation, in which the TCR directly binds to an MHC protein. For example, in transplantation situations, an APC may directly stimulate T cells through the expression of foreign MHC proteins.

[0127] The term "intracellular signaling domain," as used herein, refers to the intracellular portion of a CAR. The intracellular signaling domain generates a signal that promotes the immune effector function of the CAR-containing cell, e.g., a CAR Treg cell. For example, in a CAR Treg cell, examples of immune effector function include the suppression or downregulation of the effector function of other immune cells. Other immune cells include all types of white blood cells, such as (but not limited to) T cells, B cells, and NK cells. Additionally, the immune effector function of Tregs includes effects on non-immune cells that result in an improvement in the clinical condition, such as promoting tissue repair or regeneration.

[0128] The terms "zeta" or "zeta chain" or "CD3 zeta" are defined as the protein provided under GenBank Accession No. BAG36664.1, or equivalent residues from a non-human species (e.g., mouse, rodent, monkey, ape, etc.), and "zeta stimulatory domain" or "CD3 zeta stimulatory domain" are defined as amino acid residues from the cytoplasmic domain of the zeta chain that are sufficient for functional transmission of the initial signal required for T cell activation. In one embodiment, the cytoplasmic domain of zeta comprises residues 52-164 of GenBank Accession No. BAG36664.1, or equivalent residues from a non-human species (e.g., mouse, rodent, monkey, ape, etc.) that is its functional ortholog.

[0129] The term "costimulatory ligand," as used herein, includes a molecule on an antigen-presenting cell (e.g., an APC, a dendritic cell, a B cell, etc.) that specifically binds to a cognate costimulatory molecule on a T cell, thereby providing a signal that mediates a T cell response, including, but not limited to, proliferation, activation, differentiation, etc., in addition to the primary signal provided, for example, by binding of the TCR / CD3 complex to a peptide-loaded MHC molecule. Costimulatory ligands include CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, HVEM, agonist or antibody receptor that binds to Toll ligand, a ligand that specifically binds B7-H3, and the like. Costimulatory ligands also include, but are not limited to, MHC class I molecules, BTLA, Toll ligand receptors, OX40, CD27, CD28, lymphocyte function-associated antigen-1 (LFA-1) (CD11a / CD18), TNFR1 (CD120a / TNFRSF1A), TNFR2 (CD120b / TNFRSF1B), CTLA-4 (CD152), CD95, ICOS (CD278), 4-1BB (CD137), CD2, CD30, CD40, PD-1, CD7, LIGHT, NKG2C, B7- Ligands that specifically bind to H3, ICAM-1, GITR, HVEM, SLAMF7, NKp80, CD160, IL2ra, IL6Ra, IL-7Ra, IL-13RA1 / RA2, IL-33R (IL1RL1), IL-10RA / RB, IL-4R, IL-5R (CSF2RB), ARHR, BAFF receptor, IL-21R, TGFbR1 / 2 / 3, common gamma chain, CD83, and any combination thereof, include ligands including antibodies that specifically bind to costimulatory molecules present on T cells.

[0130] The term "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules are cell surface molecules, other than antigen receptors or their ligands, that are required for an efficient immune response. Costimulatory molecules can be represented by the following protein families: TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), and activating NK cell receptors. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA, Toll ligand receptor, OX40, CD27, CD28, lymphocyte function-associated antigen-1 (LFA-1) (CD11a / CD18), TNFR1 (CD120a / TNFRSF1A), TNFR2 (CD120b / TNFRSF1B), CTLA-4 (CD152), CD95, ICOS (CD278), 4-1BB (CD137), CD2, CD30, CD40, PD-1, CD7, LI These include ligands that specifically bind to GHT, NKG2C, B7-H3, ICAM-1, GITR, HVEM, SLAMF7, NKp80, CD160, IL2ra, IL6Ra, IL-7Ra, IL-13RA1 / RA2, IL-33R (IL1RL1), IL-10RA / RB, IL-4R, IL-5R (CSF2RB), ARHR, BAFF receptor, IL-21R, TGFbR1 / 2 / 3, common gamma chain, and CD83, and any combination thereof.

[0131] A "costimulatory intracellular signaling domain" or "costimulatory domain" can be the intracellular portion of a costimulatory molecule. Examples of such molecules include MHC class I molecules, BTLA, Toll ligand receptor, OX40, CD27, CD28, lymphocyte function-associated antigen-1 (LFA-1) (CD11a / CD18), TNFR1 (CD120a / TNFRSF1A), TNFR2 (CD120b / TNFRSF1B), CTLA-4 (CD152), CD95, ICOS (CD278), 4-1BB (CD137), CD2, CD30, CD40, PD-1, C These include ligands that specifically bind to D7, LIGHT, NKG2C, B7-H3, ICAM-1, GITR, HVEM, SLAMF7, NKp80, CD160, IL2ra, IL6Ra, IL-7Ra, IL-13RA1 / RA2, IL-33R (IL1RL1), IL-10RA / RB, IL-4R, IL-5R (CSF2RB), ARHR, BAFF receptor, IL-21R, TGFbR1 / 2 / 3, common gamma chain, and CD83.

[0132] As used herein, a "costimulatory signal" refers to a signal that, in combination with a primary signal, such as TCR / CD3 ligation, leads to T cell proliferation and / or up-regulation or down-regulation of key molecules.

[0133] The intracellular signaling domain can comprise the entire intracellular portion of the molecule from which it is derived, or the entire naturally occurring intracellular signaling domain, or a functional fragment thereof.

[0134] A "disease" is a state of health in an animal in which the animal is unable to maintain homeostasis and the animal's health continues to deteriorate if the disease is not corrected. In contrast, an animal "disorder" is a state of health in which the animal is able to maintain homeostasis, but the animal's health is not better than it would be without the disorder. If left untreated, a disorder does not necessarily result in a further decline in the animal's health.

[0135] The term "encoding" refers to the inherent property of, and the biological properties resulting from, a specific nucleotide sequence within a polynucleotide, such as a gene, cDNA, or mRNA, to serve as a template for the synthesis of other polymers and macromolecules having either a defined sequence of nucleotides (e.g., rRNA, tRNA, and mRNA) or a defined sequence of amino acids in biological processes. Thus, a gene, cDNA, or RNA encodes a protein when the protein is produced in a cell or other biological system by transcription and translation of the mRNA corresponding to that gene. Both the coding strand (whose nucleotide sequence is identical to the mRNA sequence and is usually provided in a sequence listing) and the non-coding strand (used as a template for transcription of the gene or cDNA) can be said to encode the protein or other product of that gene or cDNA.

[0136] Unless otherwise specified, a nucleotide or nucleic acid sequence that encodes an amino acid sequence includes all nucleotide or nucleic acid sequences that are degenerate versions of each other and encode the same amino acid sequence. The phrase nucleotide or nucleic acid sequence that encodes a protein or RNA may also include introns, to the extent that a nucleotide or nucleic acid sequence that encodes a protein may, in some versions, contain intron(s).

[0137] As used herein, "graft" refers to cells, tissues, or organs that are introduced into a subject. The source of the transplanted material can be cultured cells (e.g., after the cells have been cultured in vitro), cells from another subject, or cells from the same subject. Exemplary organ transplants are kidney, liver, heart, lung, and pancreas. Exemplary tissue transplants are pancreatic islets. An exemplary cell transplant is an allogeneic hematopoietic stem cell transplant.

[0138] The term "exogenous" refers to a substance introduced or produced from outside an organism, cell, tissue, or system.

[0139] The term "expression" refers to the transcription and / or translation of a particular nucleotide sequence driven by a promoter.

[0140] The term "expression vector" refers to a vector having a recombinant polynucleotide comprising expression control sequences operably linked to a nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.

[0141] The term "lentivirus" refers to a genus in the Retroviridae family. Lentiviruses are unique among retroviruses in their ability to infect non-dividing cells and are able to deliver significant amounts of genetic information into the DNA of host cells, making them one of the most efficient gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.

[0142] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, including, in particular, the self-inactivating lentiviral vector provided in Milone et al., Mol. Ther. 17(8):1453-1464 (2009). Other examples of lentiviral vectors that may be used clinically include, but are not limited to, the LENTIVECTOR® gene delivery technology from Oxford BioMedica and the LENTIMAX™ vector system from Lentigen. Non-clinical lentiviral vectors are also available and will be known to those skilled in the art.

[0143] The terms "homology" or "identity" refer to the identity of subunit sequences between two polymeric molecules, e.g., between two nucleic acid molecules such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. Two molecules are homologous or identical at a subunit position if both positions are occupied by the same monomer subunit, e.g., if each position in two DNA molecules is occupied by adenine, then they are homologous or identical at that position. The homology between two sequences is a direct function of the number of positions that are matched or homologous; for example, if half of the positions in two sequences (e.g., five positions in a polymer 10 subunits long) are homologous, then the two sequences are 50% homologous; if 90% (e.g., nine-tenths) of the positions are matched or homologous, then the two sequences are 90% homologous.

[0144] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, scFv, Fab, scFab, sdAb, Fab', F(ab)2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies and antibody fragments thereof are human immunoglobulins (recipient antibody or antibody fragment) in which residues from a complementarity-determining region (CDR) of the recipient are substituted by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies / antibody fragments may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications can further refine and optimize antibody or antibody fragment performance. Generally, a humanized antibody or antibody fragment thereof will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or a substantial portion of the FR regions are those of a human immunoglobulin sequence. The humanized antibody or antibody fragment can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525, 1986; Reichmann et al., Nature, 332:323-329, 1988; Presta, Curr. Op. Struct. Biol., 2:593-596, 1992.

[0145] A "human" immunoglobulin, antibody, or antibody fragment refers to an immunoglobulin, such as an antibody or antibody fragment, whose entire molecule is of human origin or consists of an amino acid sequence identical to a human form of an antibody or immunoglobulin.

[0146] The term "isolated" means changed or removed from the natural state. For example, a nucleic acid or peptide naturally occurring in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from coexisting materials in the natural state is. An isolated nucleic acid or protein can exist in a substantially purified form, or it can exist in a non-native environment such as, for example, a host cell. An "isolated antibody" is an antibody that has been identified and separated and / or recovered from a component of its natural environment. Contaminant components of its natural environment are substances that would interfere with therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.

[0147] In the context of the present invention, the following abbreviations are used for commonly occurring nucleic acid bases: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.

[0148] The term "operably linked" refers to a functional linkage between a regulatory sequence and a heterologous nucleic acid sequence that results in expression of the latter. For example, a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if it affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other and, for example, in the same reading frame when necessary to join two protein-coding regions.

[0149] The term "parenteral" administration of an immunogenic composition includes, for example, subcutaneous (sc), intradermal, intranodal, intramedullary, intraperitoneal, intravenous (iv), intramuscular (im) or intrasternal injection, intratumoral, or infusion techniques.

[0150] The terms "nucleic acid" or "polynucleotide," used interchangeably herein, refer to polymeric forms of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the term includes single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically, or biochemically modified, non-natural, or derivatized nucleotide bases. Thus, unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0151] The terms "peptide," "polypeptide," and "protein" are used interchangeably and refer to compounds composed of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that a protein or peptide sequence can contain. A polypeptide includes any peptide or protein containing two or more amino acids linked to each other by peptide bonds. As used herein, the term refers to both short chains (e.g., commonly referred to in the art as peptides, oligopeptides, and oligomers) and long chains (commonly referred to in the art as proteins, of which there are many types). "Polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins, among others. A polypeptide includes natural peptides, recombinant peptides, or combinations thereof.

[0152] The term "promoter / regulatory sequence" refers to a nucleic acid sequence required for expression of a gene product operably linked to the promoter / regulatory sequence. In some instances, this sequence may be a core promoter sequence, and in other instances, this sequence may also include an enhancer sequence and other regulatory elements required for expression of the gene product. The promoter / regulatory sequence may, for example, be one that confers tissue-specific expression of the gene product.

[0153] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.

[0154] The term "inducible" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced in a cell only when an inducer corresponding to the promoter is substantially present in the cell.

[0155] As used herein, "transient" refers to expression of a non-integrated transgene over a period of hours, days, or weeks, which is shorter than the period of expression of a gene when integrated into the genome or contained within a stable plasmid replicon within a host cell.

[0156] The term "substantially purified" cells refers to cells that are essentially free of other cell types. Substantially purified cells also refer to cells that have been separated from other cell types with which they are normally associated in their naturally occurring state. In some instances, a population of substantially purified cells refers to a homogenous population of cells. In other instances, the term simply refers to cells that have been separated from the cells with which they are naturally associated in their native state. In some aspects, the cells are cultured in vitro. In other aspects, the cells are not cultured in vitro.

[0157] The terms "transfect" or "transformation" or "transduction" refer to the process by which exogenous nucleic acid is transferred or introduced into a host cell. A "transfected" or "transformed" or "transduced" cell is one that has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.

[0158] Throughout this disclosure, various aspects of the invention may be presented in a range format. It will be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be construed as specifically disclosing all possible subranges within that range as well as individual numerical values. For example, description of a range such as 1 to 6 should be construed as specifically disclosing subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numbers within that range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity includes those with 95%, 96%, 97%, 98%, or 99% identity, and also includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98%, and 98-99% identity. This applies regardless of the breadth of the scope.

[0159] III. Anti-HLA-A2 antibody

[0160] In one aspect, the present invention provides anti-HLA-A2 antibodies. Exemplary antibodies include monoclonal antibodies, polyclonal antibodies, recombinant antibodies, chimeric antibodies, human antibodies, humanized antibodies, and antigen-binding fragments thereof.

[0161] In one embodiment, the present invention provides a humanized anti-HLA-A2 antibody. The humanized anti-HLA-A2 antibody provided herein specifically binds to HLA-A2. In one embodiment, the humanized anti-HLA-A2 antibody provided herein specifically binds to HLA-A*02:01. Those skilled in the art will appreciate that the ability of an antibody to bind to HLA-A2 can be detected using techniques known in the art. For example, the binding of an antibody to HLA-A2 can be detected using the HLA-A2 tetramer exemplified herein. In one embodiment, the humanized anti-HLA-A2 antibody provided herein competes for binding to HLA-A2 with an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, a humanized anti-HLA-A2 antibody provided herein binds to the same HLA-A2 epitope as an antibody having a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, a humanized anti-HLA-A2 antibody provided herein competes with the BB7.2 antibody for binding to HLA-A2.

[0162] In one embodiment, the humanized anti-HLA-A2 antibody provided herein binds to the same HLA-A2 epitope as the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from two or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from three or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from four or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from five or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody.In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from six or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from seven or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from each of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from two or more of HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody.In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least two of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least three of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least four of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least five of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least six of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least seven of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody.In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least one of HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibody provided herein has reduced reactivity with at least two of HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*25:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*29:02 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*03:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*31:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*33:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*36:01 compared to the BB7.2 antibody. In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*68:01 compared to the BB7.2 antibody.The BB7.2 antibody can be isolated from the BB7.2 hybridoma (ATCC Deposit No. HB-82).

[0163] Techniques for determining the reactivity of humanized anti-HLA-A2 antibodies to HLA-A subtypes will be known to those skilled in the art. For example, the reactivity of humanized anti-HLA-A2 antibodies to HLA-A subtypes can be determined by single antigen bead assay. Such single antigen bead assays are commercially available (e.g., FlowPRA Single Antigen Antibody; ONE LAMBDA).

[0164] In one embodiment, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, HLA-A*68, and any combination thereof, compared to the BB7.2 antibody, e.g., compared to BB7.2 scFv, when measured under the conditions of Test A. For example, in some embodiments, the humanized anti-HLA-A2 antibodies provided herein have reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*25, HLA-A*29, HLA-A*30, and any combination thereof, compared to the BB7.2 antibody, e.g., compared to BB7.2 scFv, when measured under the conditions of Test A.

[0165] Test A:

[0166] 0.25 x 10 T cells expressing a CAR containing a humanized anti-HLA-A2 antibody or a BB7.2 antibody, e.g., BB7.2 scFv (mA2 CAR) 6The beads were incubated with a FlowPRA single antigen-antibody bead panel (FL1HD01, FL1HD02, FL1HD03, FL1HD04, FL1HD06, and FL1HD08, One Lambda) and a fixable viability dye (FVD, ThermoFisher, 65-0865-14, eBioscience) for 30 minutes at room temperature. The samples were washed, fixed with 0.5% formaldehyde, and analyzed by flow cytometry. 200 negative control beads were obtained for each sample. Beads alone were used as a negative control. For analysis, dead cells were first removed using the fixable viability dye. After excluding dead cells and doublets, single antigen beads were gated. The number of beads per HLA was then determined by each PE intensity peak. Data were normalized by multiplying the number of beads of interest in each HLA peak by 200 and dividing by the number of negative beads in the sample. For each HLA peak, determine the relative binding of CAR Tregs compared to controls (non-CAR-expressing cells) by subtracting the number of CAR-Treg beads from the number of beads in the control sample, then dividing by the average number of beads in the non-CAR-expressing control, and multiplying by 100.

[0167] In one embodiment, the reactivity of the humanized anti-HLA-A2 antibody of the present invention to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 is statistically inferior to that of the BB7.2 antibody, for example, when measured under the conditions of Test A.

[0168] In one embodiment, the reactivity of the humanized anti-HLA-A2 antibody of the present invention to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 is statistically inferior to that of the BB7.2 antibody, for example, when measured under the conditions of Test A.

[0169] In one embodiment, the term "statistically inferior" means that the reactivity measured for the anti-HLA-A2 antibody of the present invention (e.g., relative binding under the conditions of Test A) is inferior to the reactivity measured for the BB7.2 antibody by a p-value of at most about 0.05, preferably at most about 0.01, more preferably at most about 0.005, and even more preferably at most about 0.001, particularly when analyzed by two-way analysis of variance with Dunnett's post-test.

[0170] In one embodiment, the anti-HLA-A2 antibody of the present invention has inferior reactivity to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In some embodiments, the anti-HLA-A2 antibody has inferior relative binding to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody, when measured under the conditions of Test A. In certain embodiments, the relative binding measured for the anti-HLA-A2 antibody is at most about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less of the relative binding measured for the BB7.2 antibody.

[0171] In one embodiment, the anti-HLA-A2 antibody of the present invention has inferior reactivity to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In some embodiments, the anti-HLA-A2 antibody has inferior relative binding to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody when measured under the conditions of Test A. In certain aspects, the relative binding measured for the anti-HLA-A2 antibody is at most about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less of the relative binding measured for the BB7.2 antibody.

[0172] Furthermore, the humanized anti-HLA-A2 antibodies having antigen-binding activity provided herein can constitute the antigen-binding domain of a chimeric antigen receptor (CAR), and the CAR can be expressed in a human cell such that the CAR specifically binds to HLA-A2. In one embodiment, the CAR specifically binds to HLA-A*02:01. As will be appreciated by those skilled in the art, the ability of a CAR to bind to HLA-A2 can be detected using techniques known in the art. For example, the binding of a CAR to HLA-A2 can be detected using an HLA-A2 tetramer as exemplified herein. In one embodiment, the human cell is an immune cell. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cell is a regulatory T cell (Treg). In one embodiment, the immune cell is a T cell. In one embodiment, the T cell is a Treg.

[0173] Furthermore, the humanized anti-HLA-A2 antibodies having antigen-binding activity provided herein can constitute the antigen-binding domain of a chimeric antigen receptor (CAR), and the CAR can be expressed in regulatory T cells (Tregs) such that the CAR specifically binds to HLA-A2. In one embodiment, the CAR specifically binds to HLA-A*02:01. In one embodiment, the Tregs are human Tregs.

[0174] In one embodiment, a humanized anti-HLA-A2 antibody can constitute the antigen-binding domain of a CAR, and the CAR can be expressed in an immune cell such that the immune cell is activated by HLA-A2. In one embodiment, the immune cell is activated by HLA-A*02:01. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cell is a regulatory T cell (Treg). In one embodiment, the immune cell is a T cell. In one embodiment, the T cell is a Treg. In one embodiment, the immune cell is a human immune cell. In one embodiment, the regulatory immune cell is a human regulatory immune cell. In one embodiment, the T cell is a human T cell. In one embodiment, the Treg is a human Treg.

[0175] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SYHIQ (SEQ ID NO: 1) and GYTFTSY (SEQ ID NO: 2).

[0176] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region having a complementarity determining region 1 (VH CDR1) selected from SEQ ID NOs: 1 to 2. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region having a VH CDR1 defined by SEQ ID NO: 1. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region having a VH CDR1 defined by SEQ ID NO: 2.

[0177] In one embodiment, the humanized anti-HLA-A2 antibody is YPGDGS (SEQ ID NO: 4) and WIYPGDGSTX 10 YX 12 X 13 KFX 16 and a heavy chain variable region comprising an amino acid sequence selected from the group consisting of: X and G (SEQ ID NO: 10), 10 ) is Q or K, and the amino acid at position 12 (X 12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 (X 16) is K or Q.

[0178] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence WIYPGDGSTX 10 YX 12 X 13 KFX 16 and a heavy chain variable region comprising a nucleotide sequence identical to that of position 10 (X 10 ) is Q or K, and the amino acid at position 12 (X 12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 (X 16 ) is K or Q.

[0179] In one embodiment, the humanized anti-HLA-A2 antibody is YPGDGS (SEQ ID NO: 4) and WIYPGDGSTX 10 YX 12 X 13 KFX 16 and a heavy chain variable region comprising a complementary chain determining region 2 (VH CDR2) comprising an amino acid sequence selected from the group consisting of: X and G (SEQ ID NO: 10), wherein the amino acid at position 10 in SEQ ID NO: 10 (X 10 ) is Q or K, and the amino acid at position 12 (X 12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 (X 16 ) is K or Q. In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence WIYPGDGSTX 10 YX 12 X 13 KFX 16 and a heavy chain variable region comprising a complementarity determining region 2 (VH CDR2) containing amino acid sequence X at position 10 (X 10 ) is Q or K, and the amino acid at position 12 (X 12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 (X 16) is K or Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is Q or K, the amino acid at position 12 is S, the amino acid at position 13 is Q, and the amino acid at position 16 is Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is K, the amino acid at position 12 is N or S, the amino acid at position 13 is Q, and the amino acid at position 16 is Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is K, the amino acid at position 12 is S, the amino acid at position 13 is E or Q, and the amino acid at position 16 is Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is K, the amino acid at position 12 is S, the amino acid at position 13 is Q, and the amino acid at position 16 is K or Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is Q or K, the amino acid at position 12 is N or S, the amino acid at position 13 is Q, and the amino acid at position 16 is Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is Q or K, the amino acid at position 12 is S, the amino acid at position 13 is E or Q, and the amino acid at position 16 is Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is Q or K, the amino acid at position 12 is S, the amino acid at position 13 is Q, and the amino acid at position 16 is K or Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is K, the amino acid at position 12 is N or S, the amino acid at position 13 is E or Q, and the amino acid at position 16 is Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is K, the amino acid at position 12 is N or S, the amino acid at position 13 is Q, and the amino acid at position 16 is K or Q.In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is K, the amino acid at position 12 is S, the amino acid at position 13 is E or Q, and the amino acid at position 16 is K or Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is Q or K, the amino acid at position 12 is N or S, the amino acid at position 13 is E or Q, and the amino acid at position 16 is Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is Q or K, the amino acid at position 12 is N or S, the amino acid at position 13 is Q, and the amino acid at position 16 is K or Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is Q or K, the amino acid at position 12 is S, the amino acid at position 13 is E or Q, and the amino acid at position 16 is K or Q. In one embodiment, the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 10, wherein the amino acid at position 10 is K, the amino acid at position 12 is N or S, the amino acid at position 13 is E or Q, and the amino acid at position 16 is K or Q.

[0180] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of WIYPGDGSTQYNEKFKG (SEQ ID NO: 3), YPGDGS (SEQ ID NO: 4), and WIYPGDGSTKYSQKFQG (SEQ ID NO: 5). In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of WIYPGDGSTQYNEKFKG (SEQ ID NO: 3) and YPGDGS (SEQ ID NO: 4). In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of YPGDGS (SEQ ID NO: 4) and WIYPGDGSTKYSQKFQG (SEQ ID NO: 5).

[0181] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising the amino acid sequence defined by SEQ ID NO: 3. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising the amino acid sequence defined by SEQ ID NO: 4. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising the amino acid sequence defined by SEQ ID NO: 5.

[0182] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region having a complementarity determining region 2 (VH CDR2) selected from SEQ ID NOs: 3 to 5. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising a complementarity determining region 2 (VH CDR2) selected from SEQ ID NOs: 3 to 4. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising a complementarity determining region 2 (VH CDR2) selected from SEQ ID NOs: 4 to 5. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising a complementarity determining region 2 (VH CDR2) defined by SEQ ID NO: 5. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising a VH CDR2 defined by SEQ ID NO: 3. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising a VH CDR2 defined by SEQ ID NO: 4.

[0183] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising the amino acid sequence EGTYYAMDY (SEQ ID NO: 6).

[0184] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region having a complementarity determining region 3 (VH CDR3) defined by SEQ ID NO:6.

[0185] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising at least one of the following CDRs: a VH CDR1 defined by SEQ ID NO: 1; or VH CDR2 defined by SEQ ID NO: 10, 10 ) is Q or K, and the amino acid at position 12 (X12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 (X 16 ) is K or Q; or VH CDR3 defined by SEQ ID NO:6.

[0186] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising at least one of the following CDRs: a VH CDR1 defined by SEQ ID NO: 1; or VH CDR2 defined by SEQ ID NO:3; or VH CDR3 defined by SEQ ID NO:6.

[0187] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising at least one of the following CDRs: a VH CDR1 defined by SEQ ID NO: 1; or VH CDR2 defined by SEQ ID NO:5; or VH CDR3 defined by SEQ ID NO:6.

[0188] In one embodiment, the humanized anti-HLA-A2 antibody comprises one VH CDR1 defined by SEQ ID NO: 1 and one VH CDR2 defined by SEQ ID NO: 10, comprising a VH CDR1 at amino acid position 10 (X 10 ) is Q or K, and the amino acid at position 12 (X 12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 (X 16 ) comprises a heavy chain variable region comprising a VH CDR2 that is K or Q and one VH CDR3 defined by SEQ ID NO:6.

[0189] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising one VH CDR1 defined by SEQ ID NO: 1, one VH CDR2 defined by SEQ ID NO: 3, and one VH CDR3 defined by SEQ ID NO: 6.

[0190] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising one VH CDR1 defined by SEQ ID NO: 1, one VH CDR2 defined by SEQ ID NO: 5, and one VH CDR3 defined by SEQ ID NO: 6.

[0191] According to the present invention, any of CDR1, 2 or 3 of the heavy chain can be characterized as having an amino acid sequence that shares at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the particular set of CDRs set forth in the corresponding SEQ ID NOs: 1, 3, 5, 6 and 10.

[0192] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising at least one of the following CDRs: a VH CDR1 defined by SEQ ID NO:2; or VH CDR2 defined by SEQ ID NO: 4; or VH CDR3 defined by SEQ ID NO:6.

[0193] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising one VH CDR1 defined by SEQ ID NO:2, one VH CDR2 defined by SEQ ID NO:4, and one VH CDR3 defined by SEQ ID NO:6.

[0194] According to the present invention, any of CDR1, 2 or 3 of the heavy chain can be characterized as having an amino acid sequence that shares at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the corresponding particular set of CDRs set forth in SEQ ID NOs: 2, 4 and 6.

[0195] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising the amino acid sequence RSSQSIVHSNGNTYLE (SEQ ID NO: 7).

[0196] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising complementarity determining region 1 (VL CDR1) defined by SEQ ID NO:7.

[0197] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising the amino acid sequence KVSNRFS (SEQ ID NO: 8).

[0198] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region having a complementarity determining region 2 (VL CDR2) defined by SEQ ID NO:8.

[0199] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising the amino acid sequence FQGSHVPRT (SEQ ID NO: 9).

[0200] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising complementarity determining region 3 (VL CDR3) defined by SEQ ID NO:9.

[0201] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising at least one of the following CDRs: VL CDR1 defined by SEQ ID NO: 7; or VL CDR2 defined by SEQ ID NO: 8; or VL CDR3 defined by SEQ ID NO:9.

[0202] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising one VL CDR1 defined by SEQ ID NO:7, one VL CDR2 defined by SEQ ID NO:8, and one VL CDR3 defined by SEQ ID NO:9.

[0203] According to the present invention, any of CDR1, 2 or 3 of the light chain can be characterized as having an amino acid sequence that shares at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the particular set of CDRs set forth in the corresponding SEQ ID NOs: 7, 8 and 9.

[0204] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising a framework region 1 (VH FR1) comprising an amino acid sequence selected from the group consisting of QVQLVQSGAEVKKPGASVKVSCKAS (SEQ ID NO: 11) and QVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 12).

[0205] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 1 (VH FR1) comprising the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKAS (SEQ ID NO: 11). In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 1 (VH FR1) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 11.

[0206] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 1 (VH FR1) comprising the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 12). In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 1 (VH FR1) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12.

[0207] In one embodiment, the humanized anti-HLA-A2 antibody WVRQAPGQX 9 LEWMGX 15 (SEQ ID NO: 13), WVRQAPGQX 9 LEWMGX 15 WI (SEQ ID NO: 17), HIQWVRQAPGQX 12 LEWMGX 18 WI (SEQ ID NO: 21), and HIQWVRQAPGQX 12 LEWMGX 18 (SEQ ID NO: 25) a heavy chain variable region comprising a framework region 2 (VH FR2) comprising an amino acid sequence selected from the group consisting of: In SEQ ID NO: 13, X 9 is R or G, and X 15 is I or absent, In SEQ ID NO: 17, X 9 is R or G, and X 15 is I or absent, In SEQ ID NO: 21, X 12 is R or G, and X 18 is I or absent, In SEQ ID NO: 25, X 12 is R or G, and X 18 is I or non-existent.

[0208] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence WVRQAPGQX 9 LEWMGX 15 (SEQ ID NO: 13), and 9 ) is R or G, and the amino acid at position 15 (X 15 ) is I or absent.

[0209] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 13, wherein the amino acid at position 9 is R or G, and the amino acid at position 15 is absent.

[0210] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 14, 15, or 16. In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 14, 15, or 16.

[0211] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence HIQWVRQAPGQX 12 LEWMGX 18 (SEQ ID NO: 25), and 12 ) is R or G, and the amino acid at position 18 (X 18 ) is I or absent.

[0212] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 25, wherein the amino acid at position 12 is R or G and the amino acid at position 18 is absent.

[0213] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 26, 27, or 28. In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 26, 27, or 28.

[0214] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence WVRQAPGQX 9 LEWMGX 15 a heavy chain variable region comprising framework region 2 (VH FR2) comprising WI (SEQ ID NO: 17), and 9) is R or G, and the amino acid at position 15 (X 15 ) is I or absent.

[0215] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 17, wherein the amino acid at position 9 is R or G, and the amino acid at position 15 is absent.

[0216] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 18, 19, or 20. In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 18, 19, or 20.

[0217] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence HIQWVRQAPGQX 12 LEWMGX 18 a heavy chain variable region comprising framework region 2 (VH FR2) comprising WI (SEQ ID NO: 21), and 12) is R or G, and the amino acid at position 18 (X 18 ) is I or absent.

[0218] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 21, wherein the amino acid at position 12 is R or G, and the amino acid at position 18 is absent.

[0219] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 22, 23, or 24. In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 22, 23, or 24.

[0220] In one embodiment, the humanized anti-HLA-A2 antibody X 1 VTX 4 TX 6 DTSX 10 STAYMX 16 LSX 19 LRSX 23 DX 25 AVYYCAR (SEQ ID NO: 29), TX 2 YX 4 X 5 KFX 8 GX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 AVYYCAR (SEQ ID NO: 35), TQYNEKFKGX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 AVYYCAR (SEQ ID NO: 36), and TKYSQKFQGX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 AVYYCAR (SEQ ID NO: 37) a heavy chain variable region comprising a framework region 3 (VH FR3) comprising an amino acid sequence selected from the group consisting of: In SEQ ID NO: 29, X 1 is R or absent, and X 4 is I or M, and X 6 is R or A, and X 10 is A, T or I, and X 16 is E or L, and X 19 is S or R, and X 23 is E or D, and X 25 is T or M, In SEQ ID NO: 35, X 2 is Q or K, and X 4 is N or S, and X 5 is E or Q, and X 8 is K or Q, and X 10 is R or absent, and X 13 is I or M, and X 15 is R or A, and X 19 is A, T or I, and X 25 is E or L, and X 28 is S or R, and X 32 is E or D, and X 34 is T or M, In SEQ ID NO: 36, X 10 is R or absent, and X 13 is I or M, and X 15 is R or A, and X 19 is A, T or I, and X 25 is E or L, and X 28 is S or R, and X 32 is E or D, and X 34 is T or M, In SEQ ID NO: 37, X 10 is R or absent, and X 13 is I or M, and X 15 is R or A, and X 19 is A, T or I, and X 25 is E or L, and X 28 is S or R, and X 32 is E or D, and X 34is T or M.

[0221] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence X 1 VTX 4 TX 6 DTSX 10 STAYMX 16 LSX 19 LRSX 23 DX 25 a heavy chain variable region comprising framework region 3 (VH FR3) comprising AVYYCAR (SEQ ID NO: 29), and 1 ) is R or absent, and the amino acid at position 4 (X 4 ) is I or M, and the amino acid at position 6 (X 6 ) is R or A, and the amino acid at position 10 (X 10 ) is A, T or I, and the amino acid at position 16 (X 16 ) is E or L, and the amino acid at position 19 (X 19 ) is S or R, and the amino acid at position 23 (X 23 ) is E or D, and the amino acid at position 25 (X 25 ) is T or M.

[0222] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 29, wherein the amino acid at position 1 is R, the amino acid at position 4 is I or M, the amino acid at position 6 is R, the amino acid at position 10 is A or I, the amino acid at position 16 is E, the amino acid at position 19 is S or R, the amino acid at position 23 is E or D, and the amino acid at position 25 is T or M.

[0223] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence defined by SEQ ID NO:29, wherein the amino acid at position 1 is R, the amino acid at position 4 is I or M, the amino acid at position 6 is R, the amino acid at position 10 is A or I, the amino acid at position 16 is E, the amino acid at position 19 is S or R, the amino acid at position 23 is E or D, and the amino acid at position 25 is T.

[0224] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence defined by SEQ ID NO:29, wherein the amino acid at position 1 is R, the amino acid at position 4 is I, the amino acid at position 6 is R, the amino acid at position 10 is A, the amino acid at position 16 is E, the amino acid at position 19 is S, the amino acid at position 23 is E, and the amino acid at position 25 is T or M.

[0225] In one embodiment, the heavy chain variable region comprises a framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 30, 31, 32, 33, or 34. In one embodiment, the heavy chain variable region comprises a framework region 3 (VH FR3) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 30, 31, 32, 33, or 34.

[0226] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence TX 2 YX 4 X 5 KFX 8 GX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 a heavy chain variable region comprising framework region 3 (VH FR3) comprising AVYYCAR (SEQ ID NO: 35), and 2 ) is Q or K, and the amino acid at position 4 (X 4 ) is N or S, and the amino acid at position 5 (X 5 ) is E or Q, and the amino acid at position 8 (X 8 ) is K or Q, and the amino acid at position 10 (X 10 ) is R or absent, and the amino acid at position 13 (X 13 ) is I or M, and the amino acid at position 15 (X 15 ) is R or A, and the amino acid at position 19 (X 19) is A, T or I, and the amino acid at position 25 (X 25 ) is E or L, and the amino acid at position 28 (X 28 ) is S or R, and the amino acid at position 32 (X 32 ) is E or D, and the amino acid at position 34 (X 34 ) is T or M.

[0227] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N or S, the amino acid at position 5 is E or Q, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0228] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N or S, the amino acid at position 5 is E or Q, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T.

[0229] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N or S, the amino acid at position 5 is E or Q, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I, the amino acid at position 15 is R, the amino acid at position 19 is A, the amino acid at position 25 is E, the amino acid at position 28 is S, the amino acid at position 32 is E, and the amino acid at position 34 is T or M.

[0230] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N, the amino acid at position 5 is E, the amino acid at position 8 is K, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0231] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q, the amino acid at position 4 is N or S, the amino acid at position 5 is E, the amino acid at position 8 is K, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0232] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q, the amino acid at position 4 is N, the amino acid at position 5 is E or Q, the amino acid at position 8 is K, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0233] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q, the amino acid at position 4 is N, the amino acid at position 5 is E, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0234] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N or S, the amino acid at position 5 is E, the amino acid at position 8 is K, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0235] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N, the amino acid at position 5 is E or Q, the amino acid at position 8 is K, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0236] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N, the amino acid at position 5 is E, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0237] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q, the amino acid at position 4 is N or S, the amino acid at position 5 is E or Q, the amino acid at position 8 is K, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0238] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q, the amino acid at position 4 is N or S, the amino acid at position 5 is E, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0239] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q, the amino acid at position 4 is N, the amino acid at position 5 is E or Q, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0240] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N or S, the amino acid at position 5 is E or Q, the amino acid at position 8 is K, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0241] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N or S, the amino acid at position 5 is E, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0242] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q or K, the amino acid at position 4 is N, the amino acid at position 5 is E or Q, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0243] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 35, wherein the amino acid at position 2 is Q, the amino acid at position 4 is N or S, the amino acid at position 5 is E or Q, the amino acid at position 8 is K or Q, the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0244] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence TQYNEKFKGX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 a heavy chain variable region comprising framework region 3 (VH FR3) comprising AVYYCAR (SEQ ID NO: 36), and 10 ) is R or absent, and the amino acid at position 13 (X 13 ) is I or M, and the amino acid at position 15 (X 15 ) is R or A, and the amino acid at position 19 (X 19 ) is A, T or I, and the amino acid at position 25 (X 25 ) is E or L, and the amino acid at position 28 (X 28 ) is S or R, and the amino acid at position 32 (X32 ) is E or D, and the amino acid at position 34 (X 34 ) is T or M.

[0245] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 36, wherein the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0246] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 36, wherein the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T.

[0247] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 36, wherein the amino acid at position 10 is R, the amino acid at position 13 is I, the amino acid at position 15 is R, the amino acid at position 19 is A, the amino acid at position 25 is E, the amino acid at position 28 is S, the amino acid at position 32 is E, and the amino acid at position 34 is T or M.

[0248] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence TKYSQKFQGX 10 VTX 13 TX 15 DTSX 19 STAYMX 25 LSX 28 LRSX 32 DX 34 a heavy chain variable region comprising framework region 3 (VH FR3) comprising AVYYCAR (SEQ ID NO: 37), and 10) is R or absent, and the amino acid at position 13 (X 13 ) is I or M, and the amino acid at position 15 (X 15 ) is R or A, and the amino acid at position 19 (X 19 ) is A, T or I, and the amino acid at position 25 (X 25 ) is E or L, and the amino acid at position 28 (X 28 ) is S or R, and the amino acid at position 32 (X 32 ) is E or D, and the amino acid at position 34 (X 34 ) is T or M.

[0249] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 37, wherein the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T or M.

[0250] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 37, wherein the amino acid at position 10 is R, the amino acid at position 13 is I or M, the amino acid at position 15 is R, the amino acid at position 19 is A or I, the amino acid at position 25 is E, the amino acid at position 28 is S or R, the amino acid at position 32 is E or D, and the amino acid at position 34 is T.

[0251] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 37, wherein the amino acid at position 10 is R, the amino acid at position 13 is I, the amino acid at position 15 is R, the amino acid at position 19 is A, the amino acid at position 25 is E, the amino acid at position 28 is S, the amino acid at position 32 is E, and the amino acid at position 34 is T or M.

[0252] In one embodiment, the heavy chain variable region comprises a framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 38, 39, 40, 41, 42, or 43. In one embodiment, the heavy chain variable region comprises a framework region 3 (VH FR3) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 38, 39, 40, 41, 42, or 43.

[0253] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 4 (VH FR4) comprising the amino acid sequence WGQGTTVTVSS (SEQ ID NO: 44). In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 4 (VH FR4) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 44.

[0254] In one embodiment, the heavy chain variable region comprises: VH CDR1 defined by SEQ ID NO: 1; VH CDR2 defined by SEQ ID NO: 10, 10 ) is Q or K, and the amino acid at position 12 (X 12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 (X 16 ) is K or Q; VH CDR3 defined by SEQ ID NO:6; VH FR1 defined by SEQ ID NO: 12; VH FR2 defined by SEQ ID NO: 13, wherein the amino acid at position 9 (X 9 ) is R or G, and the amino acid at position 15 (X 15 ) is VH FR2 that is I or absent; VH FR3 defined by SEQ ID NO: 29, wherein the amino acid at position 1 (X 1 ) is R or absent, and the amino acid at position 4 (X 4 ) is I or M, and the amino acid at position 6 (X 6 ) is R or A, and the 10th place (X 10 ) is A, T or I, and the amino acid at position 16 (X 16 ) is E or L, and the 19th position (X 19 ) is S or R, and the amino acid at position 23 (X 23 ) is E or D, and the amino acid at position 25 (X 25 ) is T or M; and VH FR4 defined by SEQ ID NO:44.

[0255] In one embodiment, the heavy chain variable region comprises: VH CDR1 defined by SEQ ID NO:2; VH CDR2 defined by SEQ ID NO: 10, 10 ) is Q or K, and the amino acid at position 12 (X 12 ) is N or S, and the amino acid at position 13 (X 13 ) is E or Q, and the amino acid at position 16 is (X 16 ) VH CDR2 that is K or Q; VH CDR3 defined by SEQ ID NO:6; VH FR1 defined by SEQ ID NO: 11; VH FR2 defined by SEQ ID NO: 25, wherein the amino acid at position 12 (X 12 ) is R or G, and the amino acid at position 18 (X 18 ) is I or absent; VH FR3 defined by SEQ ID NO: 29, wherein the amino acid at position 1 (X 1 ) is R or absent, and the amino acid at position 4 (X 4 ) is I or M, and the amino acid at position 6 (X 6 ) is R or A, and the amino acid at position 10 (X 10 ) is A, T or I, and the amino acid at position 16 (X 16) is E or L, and the amino acid at position 19 (X 19 ) is S or R, and the amino acid at position 23 (X 23 ) is E or D, and the amino acid at position 25 (X 25 ) is T or M; and VH FR4 defined by SEQ ID NO:44.

[0256] In one embodiment, the heavy chain variable region comprises: VH CDR1 defined by SEQ ID NO:2; VH CDR2 defined by SEQ ID NO:4; VH CDR3 defined by SEQ ID NO:6; VH FR1 defined by SEQ ID NO: 11; VH FR2 defined by SEQ ID NO: 21, wherein the amino acid at position 12 (X 12 ) is R or G, and the amino acid at position 18 (X 18 ) is VH FR2 that is I or absent; VH FR3 defined by SEQ ID NO: 35, wherein the amino acid at position 2 (X 2 ) is Q or K, and the amino acid at position 4 (X 4 ) is N or S, and the amino acid at position 5 (X 5 ) is E or Q, and the amino acid at position 8 (X 8 ) is K or Q, and the amino acid at position 10 (X 10 ) is R or absent, and the amino acid at position 13 (X 13 ) is I or M, and the amino acid at position 15 (X 15 ) is R or A, and the amino acid at position 19 (X 19 ) is A, T or I, and the amino acid at position 25 (X 25 ) is E or L, and the amino acid at position 28 (X 28 ) is S or R, and the amino acid at position 32 (X 32 ) is E or D, and the amino acid at position 34 (X 34 ) is T or M; and VH FR4 defined by SEQ ID NO:44.

[0257] In one embodiment, the heavy chain variable region has: VH CDR1 defined by SEQ ID NO: 1; VH CDR2 defined by SEQ ID NO:4; VH CDR3 defined by SEQ ID NO:6; VH FR1 defined by SEQ ID NO: 12; VH FR2 defined by SEQ ID NO: 17, wherein the amino acid at position 9 (X 9 ) is R or G, and the amino acid at position 15 (X 15 ) is VH FR2 that is I or absent; VH FR3 defined by SEQ ID NO: 35, wherein the amino acid at position 2 (X 2 ) is Q or K, and the amino acid at position 4 (X 4 ) is N or S, and the amino acid at position 5 (X 5 ) is E or Q, and the amino acid at position 8 (X 8 ) is K or Q, and the amino acid at position 10 (X 10 ) is R or absent, and the amino acid at position 13 (X 13 ) is I or M, and the amino acid at position 15 (X 15 ) is R or A, and the amino acid at position 19 (X 19 ) is A, T or I, and the amino acid at position 25 (X 25 ) is E or L, and the amino acid at position 28 (X 28 ) is S or R, and the amino acid at position 32 (X 32 ) is E or D, and the amino acid at position 34 (X 34 ) is T or M; and VH FR4 defined by SEQ ID NO:44.

[0258] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYHIQWVRQAPGQX 44 LEWMGX 50 WIYPGDGSTX 60 YX 62 X 63 KFX 66 GX 68 VTX 71 TX73 DTSX 77 STAYMX 83 LSX 86 LRSX 90 DX 92 a heavy chain variable region comprising: AVYYCAREGTYYAMDYWGQGTTVTVSS (SEQ ID NO: 45); and 44 ) is R or G, and the amino acid at position 50 (X 50 ) is I or absent, and the amino acid at position 60 (X 60 ) is Q or K, and the amino acid at position 62 (X 62 ) is N or S, and the amino acid at position 63 (X 63 ) is E or Q, and the amino acid at position 66 (X 66 ) is K or Q, and the amino acid at position 68 (X 68 ) is R or absent, and the amino acid at position 71 (X 71 ) is I or M, and the amino acid at position 73 (X 73 ) is R or A, and the amino acid at position 77 (X 77 ) is A, T or I, and the amino acid at position 83 (X 83 ) is E or L, and the amino acid at position 86 (X 86 ) is S or R, and the amino acid at position 90 (X 90 ) is E or D, and the amino acid at position 92 (X 92 ) is T or M.

[0259] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is N or S, the amino acid at position 63 is E or Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0260] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is N or S, the amino acid at position 63 is E or Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T.

[0261] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is N or S, the amino acid at position 63 is E or Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I, the amino acid at position 73 is R, the amino acid at position 77 is A, the amino acid at position 83 is E, the amino acid at position 86 is S, the amino acid at position 90 is E, and the amino acid at position 92 is T or M.

[0262] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q, the amino acid at position 62 is N, the amino acid at position 63 is E, the amino acid at position 66 is K, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0263] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q, the amino acid at position 62 is N, the amino acid at position 63 is E, the amino acid at position 66 is K, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T.

[0264] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R, the amino acid at position 50 is absent, the amino acid at position 60 is Q, the amino acid at position 62 is N, the amino acid at position 63 is E, the amino acid at position 66 is K, the amino acid at position 68 is R, the amino acid at position 71 is I, the amino acid at position 73 is R, the amino acid at position 77 is A, the amino acid at position 83 is E, the amino acid at position 86 is S, the amino acid at position 90 is E, and the amino acid at position 92 is T or M.

[0265] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is S, the amino acid at position 63 is Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0266] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is S, the amino acid at position 63 is Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T.

[0267] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is S, the amino acid at position 63 is Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I, the amino acid at position 73 is R, the amino acid at position 77 is A, the amino acid at position 83 is E, the amino acid at position 86 is S, the amino acid at position 90 is E, and the amino acid at position 92 is T or M.

[0268] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is S, the amino acid at position 63 is Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0269] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is N or S, the amino acid at position 63 is Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0270] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is S, the amino acid at position 63 is E or Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0271] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is N or S, the amino acid at position 63 is Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0272] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is S, the amino acid at position 63 is E or Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0273] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is S, the amino acid at position 63 is Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0274] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is N or S, the amino acid at position 63 is E or Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0275] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is N or S, the amino acid at position 63 is Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0276] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is S, the amino acid at position 63 is E or Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0277] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is N or S, the amino acid at position 63 is E or Q, the amino acid at position 66 is Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0278] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is N or S, the amino acid at position 63 is Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0279] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is Q or K, the amino acid at position 62 is S, the amino acid at position 63 is E or Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0280] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:45, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 60 is K, the amino acid at position 62 is N or S, the amino acid at position 63 is E or Q, the amino acid at position 66 is K or Q, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0281] In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 61, 62, 63, 64, 65, or 66. In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 61, 62, 63, 64, 65, or 66.

[0282] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence DX 2 VMTQX 7 PLSX 11 X 12 VTX 15 GQPASISX 23 (SEQ ID NO: 46), and 2 ) is V or I, and the amino acid at position 7 (X 7 ) is S or T, and the amino acid at position 11 (X 11 ) is L or S, and the amino acid at position 12 (X 12 ) is P or S, and the amino acid at position 15 (X 15 ) is L or P, and the amino acid at position 23 (X 23 ) is C or F.

[0283] In one embodiment, the light chain variable region comprises a framework region 1 (VL FR1) comprising the amino acid sequence set forth in SEQ ID NO: 46, wherein the amino acid at position 2 is V or I, the amino acid at position 7 is S or T, the amino acid at position 11 is L or S, the amino acid at position 12 is P or S, the amino acid at position 15 is L or P, and the amino acid at position 23 is C.

[0284] In one embodiment, the light chain variable region comprises a framework region 1 (VL FR1) comprising the amino acid sequence set forth in SEQ ID NO: 46, wherein the amino acid at position 2 is I, the amino acid at position 7 is T, the amino acid at position 11 is L or S, the amino acid at position 12 is P or S, the amino acid at position 15 is L or P, and the amino acid at position 23 is C.

[0285] In one embodiment, the light chain variable region comprises a framework region 1 (VL FR1) comprising the amino acid sequence set forth in SEQ ID NO: 46, wherein the amino acid at position 2 is V or I, the amino acid at position 7 is S or T, the amino acid at position 11 is L, the amino acid at position 12 is P or S, the amino acid at position 15 is L or P, and the amino acid at position 23 is C.

[0286] In one embodiment, the light chain variable region comprises a framework region 1 (VL FR1) comprising the amino acid sequence set forth in SEQ ID NO: 46, wherein the amino acid at position 2 is V or I, the amino acid at position 7 is S or T, the amino acid at position 11 is L or S, the amino acid at position 12 is P, the amino acid at position 15 is L, and the amino acid at position 23 is C.

[0287] In one embodiment, the light chain variable region comprises framework region 1 (VL FR1) comprising the amino acid sequence set forth in SEQ ID NO: 47, 48, 49, or 50. In one embodiment, the light chain variable region comprises framework region 4 (VH FR4) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 47, 48, 49, or 50.

[0288] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence WX 2 X 3 QX 5 PGQX 9 PX 11 X 12a light chain variable region comprising framework region 2 (VL FR2) comprising LIY (SEQ ID NO: 51), and 2 ) is F or Y, and the amino acid at position 3 (X 3 ) is Q or L, and the amino acid at position 5 (X 5 ) is R or K, and the amino acid at position 9 (X 9 ) is S or P, and the amino acid at position 11 (X 11 ) is R or Q, and the amino acid at position 12 (X 12 ) is R or L.

[0289] In one embodiment, the light chain variable region defines a framework region 2 (VL FR2) comprising the amino acid sequence set forth in SEQ ID NO: 51, wherein the amino acid at position 2 is Y, the amino acid at position 3 is Q or L, the amino acid at position 5 is R or K, the amino acid at position 9 is S or P, the amino acid at position 11 is R or Q, and the amino acid at position 12 is L.

[0290] In one embodiment, the light chain variable region comprises a framework region 2 (VL FR2) comprising the amino acid sequence set forth in SEQ ID NO: 51, wherein the amino acid at position 2 is Y, the amino acid at position 3 is Q or L, the amino acid at position 5 is R or K, the amino acid at position 9 is S, the amino acid at position 11 is R or Q, and the amino acid at position 12 is L.

[0291] In one embodiment, the light chain variable region comprises framework region 2 (VL FR2) comprising the amino acid sequence set forth in SEQ ID NO: 51, wherein the amino acid at position 2 is Y, the amino acid at position 3 is Q, the amino acid at position 5 is R, the amino acid at position 9 is S or P, the amino acid at position 11 is R, and the amino acid at position 12 is L.

[0292] In one embodiment, the light chain variable region comprises a framework region 2 (VL FR2) comprising the amino acid sequence set forth in SEQ ID NO: 51, wherein the amino acid at position 2 is F or Y, the amino acid at position 3 is Q or L, the amino acid at position 5 is R or K, the amino acid at position 9 is S, the amino acid at position 11 is R or Q, and the amino acid at position 12 is R or L.

[0293] In one embodiment, the light chain variable region comprises framework region 2 (VL FR2) comprising the amino acid sequence set forth in SEQ ID NO: 51, wherein the amino acid at position 2 is F or Y, the amino acid at position 3 is Q, the amino acid at position 5 is R, the amino acid at position 9 is S or P, the amino acid at position 11 is R, and the amino acid at position 12 is R or L.

[0294] In one embodiment, the light chain variable region comprises a framework region 2 (VL FR2) comprising the amino acid sequence set forth in SEQ ID NO: 52, 53, 54, or 55. In one embodiment, the light chain variable region comprises a framework region 2 (VL FR2) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 52, 53, 54, or 55.

[0295] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence GVPDRFSGSGX 11 a light chain variable region comprising framework region 3 (VL FR3) comprising: GTDFTLKISRVEAEDVGVYYC (SEQ ID NO: 56); and 11 ) is S or A.

[0296] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region having a framework region 3 (VL FR3) comprising the amino acid sequence set forth in SEQ ID NO: 57 or 58. In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising a framework region 3 (VL FR3) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 57 or 58.

[0297] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising framework region 4 (VL FR4) comprising the amino acid sequence FGGGTKVEIK (SEQ ID NO: 59). In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising framework region 4 (VL FR4) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 59.

[0298] In one embodiment, the humanized anti-HLA-A2 antibody has the amino acid sequence DX 2 VMTQX 7 PLSX 11 X 12 VTX 15 GQPASISX 23 RSSQSIVHSNGNTYLEWX 41 X 42 QX 44 PGQX 48 PX 50 X 51 LIYKVSNRFSGVPDRFSGSGX 72 GTDFTLKISRVEAEDVGVYYCFQGSHVPRTFGGGTKVEIK (SEQ ID NO: 60), and 2 ) is V or I, and the amino acid at position 7 (X 7 ) is S or T, and the amino acid at position 11 (X 11 ) is L or S, and the amino acid at position 12 (X 12 ) is P or S, and the amino acid at position 15 (X 15 ) is L or P, and the amino acid at position 23 (X 23 ) is C or F, and the amino acid at position 41 (X 41 ) is F or Y, and the amino acid at position 42 (X 42 ) is Q or L, and the amino acid at position 44 (X 44 ) is R or K, and the amino acid at position 48 (X 48 ) is S or P, and the amino acid at position 50 (X 50 ) is R or Q, and the amino acid at position 51 (X 51) is R or L, and the amino acid at position 72 (X 72 ) is S or A.

[0299] In one embodiment, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, wherein the amino acid at position 2 is V or I, the amino acid at position 7 is S or T, the amino acid at position 11 is L or S, the amino acid at position 12 is P or S, the amino acid at position 15 is L or P, the amino acid at position 23 is C, the amino acid at position 41 is Y, the amino acid at position 42 is Q or L, the amino acid at position 44 is R or K, the amino acid at position 48 is S or P, the amino acid at position 50 is R or Q, the amino acid at position 51 is L, and the amino acid at position 72 is S or A.

[0300] In one embodiment, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, wherein the amino acid at position 2 is I, the amino acid at position 7 is T, the amino acid at position 11 is L or S, the amino acid at position 12 is P or S, the amino acid at position 15 is L or P, the amino acid at position 23 is C, the amino acid at position 41 is Y, the amino acid at position 42 is Q or L, the amino acid at position 44 is R or K, the amino acid at position 48 is S or P, the amino acid at position 50 is R or Q, the amino acid at position 51 is L, and the amino acid at position 72 is S or A.

[0301] In one embodiment, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, wherein the amino acid at position 2 is V or I, the amino acid at position 7 is S or T, the amino acid at position 11 is L, the amino acid at position 12 is P or S, the amino acid at position 15 is L or P, the amino acid at position 23 is C, the amino acid at position 41 is Y, the amino acid at position 42 is Q or L, the amino acid at position 44 is R or K, the amino acid at position 48 is S, the amino acid at position 50 is R or Q, the amino acid at position 51 is L, and the amino acid at position 72 is S.

[0302] In one embodiment, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, wherein the amino acid at position 2 is V or I, the amino acid at position 7 is S or T, the amino acid at position 11 is L or S, the amino acid at position 12 is P, the amino acid at position 15 is L, the amino acid at position 23 is C, the amino acid at position 41 is Y, the amino acid at position 42 is Q, the amino acid at position 44 is R, the amino acid at position 48 is S or P, the amino acid at position 50 is R, the amino acid at position 51 is L, and the amino acid at position 72 is S or A.

[0303] In one embodiment, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, wherein the amino acid at position 2 is V or I, the amino acid at position 7 is S or T, the amino acid at position 11 is L or S, the amino acid at position 12 is P or S, the amino acid at position 15 is L or P, the amino acid at position 23 is C, the amino acid at position 41 is F or Y, the amino acid at position 42 is Q or L, the amino acid at position 44 is R or K, the amino acid at position 48 is S or P, the amino acid at position 50 is R or Q, the amino acid at position 51 is R or L, and the amino acid at position 72 is S or A.

[0304] In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 67, 68, 69, 70, or 71. In one embodiment, the humanized anti-HLA-A2 antibody comprises a light chain variable region comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 67, 68, 69, 70, or 71.

[0305] In one embodiment, the humanized anti-HLA-A2 antibody is an scFv, scFab, or sdAb. In one embodiment, the humanized anti-HLA-A2 antibody is an scFv or scFab. In one embodiment, the humanized anti-HLA-A2 antibody is an sdAb. In one embodiment, the humanized anti-HLA-A2 antibody is an scFab. In one embodiment, the humanized anti-HLA-A2 antibody is an scFv. In one embodiment, the humanized anti-HLA-A2 antibody is an scFv comprising the amino acid sequence set forth in SEQ ID NO: 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or 91. In one embodiment, the humanized anti-HLA-A2 antibody is an scFv comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 or 91.

[0306] In one embodiment, the humanized anti-HLA-A2 antibody comprises an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the above SEQ ID NOs: 1 and 2. In one embodiment, the humanized anti-HLA-A2 antibody is an scFv or scFab comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the above SEQ ID NOs:

[0307] In one aspect, the invention provides an anti-HLA antibody comprising a heavy chain variable region comprising the amino acid sequence WIYPGDGSTKYSQKFQG (SEQ ID NO: 5).

[0308] In one embodiment, the antibody is an antibody mimetic selected from the group consisting of an affibody, an alphabody, an armadillo repeat protein-based scaffold, a knottin, a Kunitz domain peptide, an affilin, an affitin, an adnectin, an atrimer, an evasin, a DARPin, an anticalin, an avimer, a finomer, a versabody, and a duocalin.

[0309] The anti-HLA-A2 antibodies provided herein specifically bind to HLA-A2. In one embodiment, the anti-HLA-A2 antibodies provided herein specifically bind to HLA-A*02:01. Those skilled in the art will appreciate that the ability of an antibody to bind to HLA-A2 can be detected by techniques known in the art. For example, the binding of an antibody to HLA-A2 can be detected by using the HLA-A2 tetramer exemplified herein. In one embodiment, the anti-HLA-A2 antibody provided herein competes for binding to HLA-A2 with an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, the anti-HLA-A2 antibody provided herein binds to the same HLA-A2 epitope as an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, the anti-HLA-A2 antibody provided herein competes with the BB7.2 antibody for binding to HLA-A2. In one embodiment, the anti-HLA-A2 antibody provided herein binds to the same HLA-A2 epitope as the BB7.2 antibody. In one embodiment, the anti-HLA antibody comprises a heavy chain variable region comprising complementarity determining region 2 (VH CDR2) defined by SEQ ID NO:5.In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from two or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from three or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from four or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from five or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from six or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody.In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from seven or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from each of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from two or more of HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has reduced reactivity with at least one HLA-A subtype selected from each of HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least one of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least two of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody.In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least three of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least four of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least five of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least six of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least seven of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to the BB7.2 antibody.In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least one of HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with at least two of HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have reduced reactivity with HLA-A*25:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*29:02 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*30:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*03:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*31:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*33:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibodies provided herein have lower reactivity with HLA-A*36:01 compared to the BB7.2 antibody. In one embodiment, the anti-HLA-A2 antibody provided herein has lower reactivity to HLA-A*68:01 compared to the BB7.2 antibody. The BB7.2 antibody can be isolated from the BB7.2 hybridoma (ATCC deposit number HB-82). Techniques for determining the reactivity of an anti-HLA-A2 antibody to an HLA-A subtype will be known to those skilled in the art. For example, the reactivity of an anti-HLA-A2 antibody to an HLA-A subtype can be determined by a single antigen bead assay.Such single antigen bead assays are commercially available (e.g., FlowPRA Single Antigen Antibody; ONE LAMBDA).

[0310] In one embodiment, the anti-HLA-A2 antibodies provided herein have lower reactivity with at least one HLA-A subtype selected from one or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, HLA-A*68, and any combination thereof, compared to the BB7.2 antibody, when measured under the conditions of Test A. For example, in some embodiments, the anti-HLA-A2 antibodies provided herein have lower reactivity with at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, HLA-A*30, and any combination thereof, compared to the BB7.2 antibody, when measured under the conditions of Test A.

[0311] Test A:

[0312] 0.25 x 10 T cells expressing a CAR comprising an anti-HLA-A2 antibody or a BB7.2 antibody (e.g., BB7.2 scFv (mA2 CAR)) 6The beads were incubated with a FlowPRA single antigen-antibody bead panel (FL1HD01, FL1HD02, FL1HD03, FL1HD04, FL1HD06, and FL1HD08, One Lambda) and a fixable viability dye (FVD, ThermoFisher, 65-0865-14, eBioscience) for 30 minutes at room temperature. The samples were washed, fixed with 0.5% formaldehyde, and analyzed by flow cytometry. 200 negative control beads were obtained for each sample. Beads alone were used as a negative control. For analysis, dead cells were first removed using the fixable viability dye. After excluding dead cells and doublets, single antigen beads were gated. The number of beads per HLA was then determined by each PE intensity peak. Data were normalized by multiplying the number of beads of interest in each HLA peak by 200 and dividing by the number of negative beads in the sample. For each HLA peak, determine the relative binding of CAR Tregs compared to controls (non-CAR-expressing cells) by subtracting the number of CAR-Treg beads from the number of beads in the control sample, then dividing by the average number of beads in the non-CAR-expressing control, and multiplying by 100.

[0313] In one embodiment, the reactivity of the anti-HLA-A2 antibody of the present invention to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 is statistically inferior to that of the BB7.2 antibody, for example, when measured under the conditions of Test A.

[0314] In one embodiment, the reactivity of the anti-HLA-A2 antibody of the present invention to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 is statistically inferior to that of the BB7.2 antibody, for example, when measured under the conditions of Test A.

[0315] In one embodiment, the term "statistically inferior" means that the reactivity measured for the anti-HLA-A2 antibody of the present invention (e.g., relative binding under the conditions of Test A) is inferior to the reactivity measured for the BB7.2 antibody by a p-value of at most about 0.05, preferably at most about 0.01, more preferably at most about 0.005, and even more preferably at most about 0.001, particularly when analyzed by two-way analysis of variance with Dunnett's post-test.

[0316] In one embodiment, the anti-HLA-A2 antibody of the present invention has inferior reactivity to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody. In some embodiments, the anti-HLA-A2 antibody has inferior relative binding to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to the BB7.2 antibody, when measured under the conditions of Test A. In certain embodiments, the relative binding measured for the anti-HLA-A2 antibody is at most about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less of the relative binding measured for the BB7.2 antibody.

[0317] In one embodiment, the anti-HLA-A2 antibody of the present invention has inferior reactivity to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody. In some embodiments, the anti-HLA-A2 antibody has inferior relative binding to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 compared to the BB7.2 antibody when measured under the conditions of Test A. In certain aspects, the relative binding measured for the anti-HLA-A2 antibody is at most about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less of the relative binding measured for the BB7.2 antibody.

[0318] Furthermore, the anti-HLA-A2 antibodies having antigen-binding activity provided herein can constitute the antigen-binding domain of a CAR, which can be expressed in a human cell such that the CAR specifically binds to HLA-A2. In one embodiment, the CAR specifically binds to HLA-A*02:01. As will be understood by those skilled in the art, the ability of a CAR to bind to HLA-A2 can be detected by using techniques known in the art. For example, the binding of a CAR to HLA-A2 can be detected by using an HLA-A2 tetramer as exemplified herein. In one embodiment, the human cell is an immune cell. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cell is a regulatory T cell (Treg). In one embodiment, the immune cell is a T cell. In one embodiment, the T cell is a Treg.

[0319] Furthermore, the anti-HLA-A2 antibodies having antigen-binding activity provided herein can constitute the antigen-binding domain of a chimeric antigen receptor (CAR), and the CAR can be expressed in regulatory T cells (Tregs) such that the CAR specifically binds to HLA-A2. In one embodiment, the CAR specifically binds to HLA-A*02:01. In one embodiment, the Tregs are human Tregs.

[0320] In one embodiment, an anti-HLA-A2 antibody can constitute the antigen-binding domain of a CAR, and the CAR can be expressed in an immune cell such that the immune cell is activated by HLA-A2. In one embodiment, the immune cell is activated by HLA-A*02:01. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cell is a regulatory T cell (Treg). In one embodiment, the immune cell is a T cell. In one embodiment, the T cell is a Treg. In one embodiment, the immune cell is a human immune cell. In one embodiment, the regulatory immune cell is a human regulatory immune cell. In one embodiment, the T cell is a human T cell. In one embodiment, the Treg is a human Treg.

[0321] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SYHIQ (SEQ ID NO: 1) and GYTFTSY (SEQ ID NO: 2).

[0322] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising a complementarity determining region 1 (VH CDR1) selected from SEQ ID NOs: 1 to 2. In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising a VH CDR1 defined by SEQ ID NO: 1. In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region having a VH CDR1 defined by SEQ ID NO: 2.

[0323] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising the amino acid sequence EGTYYAMDY (SEQ ID NO: 6).

[0324] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising a complementarity determining region 3 (VH CDR3) defined by SEQ ID NO:6.

[0325] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising one VH CDR2 defined by SEQ ID NO:5 and at least one of the following CDRs: a VH CDR1 defined by SEQ ID NO: 1; or VH CDR3 defined by SEQ ID NO:6.

[0326] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising one VH CDR1 defined by SEQ ID NO: 1, one VH CDR2 defined by SEQ ID NO: 5, and one VH CDR3 defined by SEQ ID NO: 6.

[0327] According to the present invention, any of CDR1, 2 or 3 of the heavy chain can be characterized as having an amino acid sequence that shares at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the particular set of CDRs set forth in the corresponding SEQ ID NOs: 1, 5 and 6.

[0328] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising one VH CDR2 defined by SEQ ID NO:5 and at least one of the following CDRs: a VH CDR1 defined by SEQ ID NO:2; or a VH CDR3 defined by SEQ ID NO:6.

[0329] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising one VH CDR1 defined by SEQ ID NO:2, one VH CDR2 defined by SEQ ID NO:5, and one VH CDR3 defined by SEQ ID NO:6.

[0330] According to the present invention, any of CDR1, 2 or 3 of the heavy chain can be characterized as having an amino acid sequence that shares at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the corresponding particular set of CDRs set forth in SEQ ID NOs: 2, 5 and 6.

[0331] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region comprising the amino acid sequence RSSQSIVHSNGNTYLE (SEQ ID NO: 7).

[0332] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region comprising complementarity determining region 1 (VL CDR1) defined by SEQ ID NO:7.

[0333] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region comprising the amino acid sequence KVSNRFS (SEQ ID NO: 8).

[0334] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region comprising a complementarity determining region 2 (VL CDR2) defined by SEQ ID NO:8.

[0335] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region comprising the amino acid sequence FQGSHVPRT (SEQ ID NO: 9).

[0336] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region comprising a complementarity determining region 3 (VL CDR3) defined by SEQ ID NO:9.

[0337] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region having at least one of the following CDRs: VL CDR1 defined by SEQ ID NO: 7; or VL CDR2 defined by SEQ ID NO: 8; or VL CDR3 defined by SEQ ID NO:9.

[0338] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region comprising one VL CDR1 defined by SEQ ID NO:7, one VL CDR2 defined by SEQ ID NO:8, and one VL CDR3 defined by SEQ ID NO:9.

[0339] According to the present invention, any of CDR1, 2 or 3 of the light chain can be characterized as having an amino acid sequence that shares at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the corresponding particular set of CDRs set forth in SEQ ID NOs: 7, 8 and 9.

[0340] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising a framework region 1 (VH FR1) comprising an amino acid sequence selected from the group consisting of QVQLVQSGAEVKKPGASVKVSCKAS (SEQ ID NO: 11) and QVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 12).

[0341] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising a framework region 1 (VH FR1) comprising the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKAS (SEQ ID NO: 11). In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising a framework region 1 (VH FR1) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 11.

[0342] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 1 (VH FR1) comprising the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 12). In one embodiment, the humanized anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 1 (VH FR1) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12.

[0343] In one embodiment, the anti-HLA-A2 antibody is 9 LEWMGX 15 (SEQ ID NO: 13) and HIQWVRQAPGQX 12 LEWMGX 18 (SEQ ID NO: 25), and in SEQ ID NO: 13, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising an amino acid sequence selected from the group consisting of X 9is R or G, and X 15 is I or absent, and in SEQ ID NO: 25, X 12 is R or G, and X 18 is I or non-existent.

[0344] In one embodiment, the anti-HLA-A2 antibody has the amino acid sequence WVRQAPGQX 9 LEWMGX 15 (SEQ ID NO: 13), and 9 ) is R or G, and the amino acid at position 15 (X 15 ) is I or absent.

[0345] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 13, wherein the amino acid at position 9 is R or G and the amino acid at position 15 is absent.

[0346] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 14, 15, or 16. In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 14, 15, or 16.

[0347] In one embodiment, the anti-HLA-A2 antibody has the amino acid sequence HIQWVRQAPGQX 12 LEWMGX 18 (SEQ ID NO: 25), and 12 ) is R or G, and the amino acid at position 18 (X 18 ) is I or absent.

[0348] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 25, wherein the amino acid at position 12 is R or G and the amino acid at position 18 is absent.

[0349] In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising the amino acid sequence set forth in SEQ ID NO: 26, 27, or 28. In one embodiment, the heavy chain variable region comprises a framework region 2 (VH FR2) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 26, 27, or 28.

[0350] In one embodiment, the anti-HLA-A2 antibody has the amino acid sequence X 1 VTX 4 TX 6 DTSX 10 STAYMX 16 LSX 19 LRSX 23 DX 25 a heavy chain variable region comprising framework region 3 (VH FR3) comprising AVYYCAR (SEQ ID NO: 29), and 1 ) is R or absent, and the amino acid at position 4 (X 4 ) is I or M, and the amino acid at position 6 (X 6 ) is R or A, and the amino acid at position 10 (X 10 ) is A, T or I, and the amino acid at position 16 (X 16 ) is E or L, and the amino acid at position 19 (X 19 ) is S or R, and the amino acid at position 23 (X 23 ) is E or D, and the amino acid at position 25 (X 25 ) is T or M.

[0351] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 29, wherein the amino acid at position 1 is R, the amino acid at position 4 is I or M, the amino acid at position 6 is R, the amino acid at position 10 is A or I, the amino acid at position 16 is E, the amino acid at position 19 is S or R, the amino acid at position 23 is E or D, and the amino acid at position 25 is T or M.

[0352] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence defined by SEQ ID NO:29, wherein the amino acid at position 1 is R, the amino acid at position 4 is I or M, the amino acid at position 6 is R, the amino acid at position 10 is A or I, the amino acid at position 16 is E, the amino acid at position 19 is S or R, the amino acid at position 23 is E or D, and the amino acid at position 25 is T.

[0353] In one embodiment, the heavy chain variable region comprises framework region 3 (VH FR3) comprising the amino acid sequence defined by SEQ ID NO:29, wherein the amino acid at position 1 is R, the amino acid at position 4 is I, the amino acid at position 6 is R, the amino acid at position 10 is A, the amino acid at position 16 is E, the amino acid at position 19 is S, the amino acid at position 23 is E, and the amino acid at position 25 is T or M.

[0354] In one embodiment, the heavy chain variable region comprises a framework region 3 (VH FR3) comprising the amino acid sequence set forth in SEQ ID NO: 30, 31, 32, 33, or 34. In one embodiment, the heavy chain variable region comprises a framework region 3 (VH FR3) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 30, 31, 32, 33, or 34.

[0355] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 4 (VH FR4) comprising the amino acid sequence WGQGTTVTVSS (SEQ ID NO: 44). In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising framework region 4 (VH FR4) comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 44.

[0356] In one embodiment, the heavy chain variable region comprises: VH CDR1 defined by SEQ ID NO: 1; VH CDR2 defined by SEQ ID NO:5; VH CDR3 defined by SEQ ID NO:6; VH FR1 defined by SEQ ID NO: 12; VH FR2 defined by SEQ ID NO: 13, wherein the amino acid at position 9 (X 9 ) is R or G, and the amino acid at position 15 (X 15 ) is VH FR2 that is I or absent; VH FR3 defined by SEQ ID NO: 29, wherein the amino acid at position 1 (X 1 ) is R or absent, and the amino acid at position 4 (X 4 ) is I or M, and the amino acid at position 6 (X 6 ) is R or A, and the 10th place (X 10 ) is A, T or I, and the amino acid at position 16 (X 16 ) is E or L, and the 19th position (X 19 ) is S or R, and the amino acid at position 23 (X 23 ) is E or D, and the amino acid at position 25 (X 25 ) is T or M; and VH FR4 defined by SEQ ID NO:44.

[0357] In one embodiment, the heavy chain variable region comprises: VH CDR1 defined by SEQ ID NO:2; VH CDR2 defined by SEQ ID NO:5; VH CDR3 defined by SEQ ID NO:6; VH FR1 defined by SEQ ID NO: 11; VH FR2 defined by SEQ ID NO: 25, wherein the amino acid at position 12 (X 12 ) is R or G, and the amino acid at position 18 (X 18 ) is I or absent; VH FR3 defined by SEQ ID NO: 29, wherein the amino acid at position 1 (X 1 ) is R or absent, and the amino acid at position 4 (X 4 ) is I or M, and the amino acid at position 6 (X 6 ) is R or A, and the amino acid at position 10 (X 10 ) is A, T or I, and the amino acid at position 16 (X 16 ) is E or L, and the amino acid at position 19 (X 19 ) is S or R, and the amino acid at position 23 (X 23 ) is E or D, and the amino acid at position 25 (X 25 ) is T or M; and VH FR4 defined by SEQ ID NO:44.

[0358] In one embodiment, the anti-HLA-A2 antibody has the amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYHIQWVRQAPGQX 44 LEWMGX 50 WIYPGDGSTKYSQKFQGX 68 VTX 71 TX 73 DTSX 77 STAYMX 83 LSX 86 LRSX 90 DX 92AVYYCAREGTYYAMDYWGQGTTVTVSS (SEQ ID NO: 92), wherein the amino acid at position 44 is R or G, the amino acid at position 50 is I or absent, the amino acid at position 68 is R or absent, the amino acid at position 71 is I or M, the amino acid at position 73 is R or A, the amino acid at position 77 is A, T, or I, the amino acid at position 83 is E or L, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0359] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T or M.

[0360] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92, wherein the amino acid at position 44 is R or G, the amino acid at position 50 is absent, the amino acid at position 68 is R, the amino acid at position 71 is I or M, the amino acid at position 73 is R, the amino acid at position 77 is A or I, the amino acid at position 83 is E, the amino acid at position 86 is S or R, the amino acid at position 90 is E or D, and the amino acid at position 92 is T.

[0361] In one embodiment, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92, wherein the amino acid at position 44 is R, the amino acid at position 50 is absent, the amino acid at position 68 is R, the amino acid at position 71 is I, the amino acid at position 73 is R, the amino acid at position 77 is A, the amino acid at position 83 is E, the amino acid at position 86 is S, the amino acid at position 90 is E, and the amino acid at position 92 is T or M.

[0362] In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 66. In one embodiment, the anti-HLA-A2 antibody comprises a heavy chain variable region comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:66.

[0363] In one embodiment, the anti-HLA-A2 antibody comprises a light chain variable region defined anywhere herein. For example, in one embodiment, the anti-HLA-A2 antibody may comprise a light chain variable region defined anywhere herein for a humanized anti-HLA-A2 antibody.

[0364] In one embodiment, the anti-HLA-A2 antibody is an scFv, scFab, or sdAb. In one embodiment, the anti-HLA-A2 antibody is an scFv or scFab. In one embodiment, the anti-HLA-A2 antibody is an sdAb. In one embodiment, the anti-HLA-A2 antibody is an scFab. In one embodiment, the anti-HLA-A2 antibody is an scFv. In one embodiment, the anti-HLA-A2 antibody is an scFv comprising the amino acid sequence set forth in SEQ ID NO: 91. In one embodiment, the anti-HLA-A2 antibody is an scFv comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 91.

[0365] In one embodiment, the anti-HLA-A2 antibody is a humanized anti-HLA-A2 antibody. In one embodiment, the anti-HLA-A2 antibody is a human antibody. In one embodiment, the anti-HLA-A2 antibody is a non-humanized antibody. In one embodiment, the anti-HLA-A2 antibody is a non-human antibody.

[0366] In one embodiment, the anti-HLA-A2 antibody comprises an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the above SEQ ID NOs: 1 and 2. In one embodiment, the anti-HLA-A2 antibody is an scFv or scFab comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the above SEQ ID NOs:

[0367] Compositions comprising, consisting essentially of, or consisting of at least one anti-HLA-A2 antibody of the invention are also provided.

[0368] As used herein, "consisting essentially of" with respect to a composition means that at least one anti-HLA-A2 antibody of the present invention as described above is the only therapeutic agent or drug having biological activity in the composition.

[0369] In another embodiment, a pharmaceutical composition is provided comprising at least one anti-HLA-A2 antibody of the invention and a pharmaceutically acceptable carrier.

[0370] In one embodiment, the anti-HLA-A2 antibody is a humanized anti-HLA-A2 antibody.

[0371] Examples of pharmaceutically acceptable carriers include, but are not limited to, vehicles, solvents, coatings, isotonic and absorption delaying agents, additives, stabilizers, preservatives, surfactants, substances that inhibit enzymatic degradation, alcohols, pH adjusters, antioxidants; chelating agents such as EDTA and glutathione; adjuvants (e.g., aluminum hydroxide); preservatives and propellants.

[0372] Examples of pharmaceutically acceptable vehicles include, but are not limited to, water, neutral buffered saline, phosphate buffered saline, saline or other physiologically buffered saline, or other solvents such as glycols, glycerol, and oils such as olive oil or injectable organic esters. Pharmaceutically acceptable vehicles can also include liposomes or micelles.

[0373] Examples of coating materials include, but are not limited to, lecithin.

[0374] Examples of isotonic agents include, but are not limited to, sugars, sodium chloride, and the like.

[0375] Examples of agents that delay absorption include, but are not limited to, aluminum monostearate and gelatin.

[0376] Examples of additives include, but are not limited to, mannitol, dextran, carbohydrates (e.g., glucose, mannose, sucrose, or dextran); glycine, lactose, or polyvinylpyrrolidone, or other additives suitable for in vivo administration, such as antioxidants, inert gases, stabilizers, recombinant proteins (e.g., human serum albumin), etc.

[0377] Examples of suitable stabilizers include, but are not limited to, sucrose, gelatin, peptone, digested protein extracts such as NZ-amine and NZ-amine AS.

[0378] Pharmaceutically acceptable carriers that can be used in these compositions further include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene polyoxypropylene block polymers, polyethylene glycol, and wool fat.

[0379] Also provided is a medicament comprising, consisting of, or consisting essentially of at least one anti-HLA-A2 antibody of the invention as described above. In one embodiment, the anti-HLA-A2 antibody is a humanized anti-HLA-A2 antibody.

[0380] IV. Chimeric Antigen Receptors (CARs)

[0381] In one aspect, the present invention provides chimeric antigen receptors (CARs), which are chimeric protein molecules that combine antibody-based specificity for a target antigen with an immune cell receptor activating intracellular domain.

[0382] The CAR of the present invention comprises an extracellular domain that specifically binds to HLA-A2. The extracellular domain comprises an anti-HLA-A2 antibody of the present invention. In one embodiment, the anti-HLA-A2 antibody is a humanized anti-HLA-A2 antibody. The CAR of the present invention further comprises a transmembrane domain and a cytoplasmic domain that includes an intracellular signaling domain. In one embodiment, the CAR of the present invention can be expressed in a human cell such that the CAR specifically binds to HLA-A2. In another embodiment, the CAR of the present invention can be expressed in an immune cell such that the CAR specifically binds to HLA-A2. In one embodiment, the CAR specifically binds to HLA-A*02:01. As will be appreciated by those skilled in the art, the ability of an antibody to bind to HLA-A2 can be detected using techniques known in the art. For example, the binding of a CAR to HLA-A2 can be detected using the HLA-A2 tetramer exemplified herein. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from two or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity to at least one HLA-A subtype selected from three or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody.In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from four or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from five or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from six or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from seven or more of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from each of HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from one or more of HLA-A*25, HLA-A*29, and HLA-A*30 compared to a CAR comprising the BB7.2 antibody.In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from two or more of HLA-A*25, HLA-A*29, and HLA-A*30 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one HLA-A subtype selected from each of HLA-A*25, HLA-A*29, and HLA-A*30 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least two of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least three of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity to at least four of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody.In one embodiment, a CAR provided herein has reduced reactivity with at least five of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least six of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least seven of HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*03:01, HLA-A*25:01, HLA-A*29:02, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-A*36:01, and HLA-A*68:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least one of HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with at least two of HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*25:01, HLA-A*29:02, and HLA-A*30:01 compared to a CAR comprising the BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*25:01 compared to a CAR comprising the BB7.2 antibody.In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*29:02 compared to a CAR comprising a BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*30:01 compared to a CAR comprising a BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*03:01 compared to a CAR comprising a BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*31:01 compared to a CAR comprising a BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*33:01 compared to a CAR comprising a BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*36:01 compared to a CAR comprising a BB7.2 antibody. In one embodiment, a CAR provided herein has reduced reactivity with HLA-A*68:01 compared to a CAR comprising a BB7.2 antibody. In one embodiment, the human cell is an immune cell. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cells are regulatory T cells (Tregs). In one embodiment, the immune cells are T cells. In one embodiment, the T cells are Tregs.

[0383] The technique for determining the reactivity of CAR of the present invention to HLA-A subtype will be known to those skilled in the art.For example, the reactivity of CAR of the present invention to HLA-A subtype can be determined by single antigen bead assay.Such single antigen bead assay is commercially available (for example, FlowPRA Single Antigen Antibody; ONE LAMBDA).

[0384] In one embodiment, a CAR of the present invention has reduced reactivity to an HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, HLA-A*68, and any combination thereof, compared to a CAR comprising the BB7.2 antibody, when measured under the conditions of Test A described herein above.

[0385] In one embodiment, a CAR of the present invention has reduced reactivity to an HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, HLA-A*30, and any combination thereof, compared to a CAR comprising the BB7.2 antibody, when measured under the conditions of Test A described herein above.

[0386] In one embodiment, the reactivity of a CAR of the present invention to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 is statistically inferior to that of a CAR comprising the BB7.2 antibody, for example, when measured under the conditions of Test A.

[0387] In one embodiment, the reactivity of a CAR of the present invention to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 is statistically inferior to that of a CAR comprising the BB7.2 antibody, for example, when measured under the conditions of Test A.

[0388] In one embodiment, the term "statistically inferior" means that the reactivity measured for a CAR of the present invention (e.g., relative binding under the conditions of Test A) is inferior to the reactivity measured for a CAR comprising the BB7.2 antibody by a p-value of at most about 0.05, preferably at most about 0.01, more preferably at most about 0.005, and even more preferably at most about 0.001, particularly when analyzed by two-way analysis of variance, Dunnett's post-test.

[0389] In one embodiment, a CAR of the invention is less reactive to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 than a CAR comprising the BB7.2 antibody. In some embodiments, the CAR is less reactive to at least one HLA-A subtype selected from the group including HLA-A*03, HLA-A*25, HLA-A*29, HLA-A*30, HLA-A*31, HLA-A*33, HLA-A*36, and HLA-A*68 than a CAR comprising the BB7.2 antibody, as measured under the conditions of Test A. In certain embodiments, the relative binding of the CAR is up to about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less of the relative binding measured for a CAR comprising the BB7.2 antibody.

[0390] In one embodiment, a CAR of the present invention is less reactive to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 than a CAR comprising the BB7.2 antibody. In some embodiments, the CAR has less relative binding to at least one HLA-A subtype selected from the group including HLA-A*25, HLA-A*29, and HLA-A*30 than a CAR comprising the BB7.2 antibody, when measured under the conditions of Test A. In certain aspects, the relative binding measured for the CAR is at most about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or less of the binding of a CAR comprising the BB7.2 antibody.

[0391] In one embodiment, the CAR can be expressed in an immune cell such that the immune cell is activated by HLA-A2. In one embodiment, the immune cell is activated by HLA-A*02:01. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cell is a regulatory T cell (Treg). In one embodiment, the immune cell is a T cell. In one embodiment, the T cell is a Treg. In one embodiment, the immune cell is a human immune cell. In one embodiment, the regulatory immune cell is a human regulatory immune cell. In one embodiment, the T cell is a human T cell. In one embodiment, the Treg is a human Treg.

[0392] In one embodiment, the CAR competes for binding to HLA-A2 with an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, the CAR binds to the same HLA-A2 epitope as an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, the CAR competes with the BB7.2 antibody for binding to HLA-A2. In one embodiment, the CAR binds to the same HLA-A2 epitope as the BB7.2 antibody. The BB7.2 antibody can be isolated from the BB7.2 hybridoma (ATCC Deposit No. HB-82).

[0393] In one embodiment, the CAR of the present invention comprises an extracellular domain comprising an anti-HLA-A2 antibody, a transmembrane domain, and a cytoplasmic domain comprising an intracellular signaling domain. In one embodiment, the anti-HLA-A2 antibody is a humanized anti-HLA-A2 antibody.

[0394] In one embodiment, the chimeric receptor further comprises a tag and / or a leader sequence.

[0395] In one embodiment, the chimeric receptor further comprises a tag, such as a tag for quality control, enrichment, in vivo tracking, etc. The tag may be located at the N-terminus, C-terminus, and / or internally. Examples of tags that can be used in the chimeric receptor of the present invention are well known to those skilled in the art. For example, but not limited to, the tag used in the present invention may be a tag selected from the group including or consisting of a hemagglutinin tag, a polyarginine tag, a polyhistidine tag, a Myc tag, a Strep tag, an S-Tag, an HAT tag, a 3xFlag tag, a calmodulin-binding peptide tag, an SBP tag, a chitin-binding domain tag, a GST tag, a maltose-binding protein tag, a fluorescent protein tag (e.g., eGFP), a T7 tag, a V5 tag, and an Xpress tag.

[0396] The extracellular domain is a target-specific binding element, also referred to as the targeting arm of the CAR. The extracellular domain is selected to recognize a ligand that acts as a cell surface marker on target cells associated with a particular pathology. The CAR of the present invention is engineered to target cells that present HLA-A2 by engineering an appropriate extracellular domain that specifically binds to an HLA-A2 epitope. The target-specific binding element or antigen-binding domain of the CAR of the present invention may be referred to herein as an anti-HLA-A2 binding domain. In some embodiments, the anti-HLA-A2 binding domain may be a humanized anti-HLA-A2 binding domain.

[0397] The transmembrane domain is attached to the extracellular and cytoplasmic domains of the CAR. The transmembrane domain is capable of signaling to the intracellular signaling domain(s) of the cytoplasmic domain whenever the extracellular domain of the CAR binds to a target.

[0398] The cytoplasmic domain, including the intracellular signaling domain, of a CAR is involved in activating at least one physiological effector function of an immune cell (e.g., a regulatory T cell) to which the CAR is placed. The term "effector function" refers to a specialized function of an immune cell. For example, the effector function of a regulatory T cell may include suppressing or downregulating the induction and / or proliferation of other immune cells. Furthermore, the effector function of a Treg may include an effect on non-immune cells that results in an improvement in a clinical condition, such as promoting tissue repair or regeneration. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal and instructs an immune cell to perform its specialized function. Typically, the entire intracellular signaling domain can be employed, although in many cases, it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such a truncated portion may be used in place of the intact chain, so long as it transmits the effector function signal. Thus, the term intracellular signaling domain is intended to include a truncated portion of the intracellular signaling domain sufficient to transmit the effector function signal.

[0399] In one embodiment, a spacer domain (or linker or hinge) may be incorporated between the antigen binding domain and the transmembrane domain of the CAR, or between the intracellular signaling domain and the transmembrane domain of the CAR. As defined above, spacer domains, linkers, and hinges are oligopeptides or polypeptides that function to link the transmembrane domain to either the antigen binding domain or the intracellular signaling domain of the polypeptide chain. A spacer domain may comprise, for example, up to 300 amino acids, 10-100 amino acids, 25-75 amino acids, or 25-50 amino acids, or any subrange or individual number of amino acids within these ranges.

[0400] Extracellular domain

[0401] The extracellular domain comprises an anti-HLA-A2 antibody of the invention. In one embodiment, the extracellular domain comprises a humanized anti-HLA-A2 antibody of the invention.

[0402] In one embodiment, the extracellular domain comprises an anti-HLA-A2 antibody of the invention that is an scFv, scFab, or sdAb. In one embodiment, the extracellular domain comprises an anti-HLA-A2 antibody of the invention that is an scFv or scFab. In one embodiment, the extracellular domain comprises an anti-HLA-A2 antibody of the invention that is an sdAb. In one embodiment, the extracellular domain comprises an anti-HLA-A2 antibody of the invention that is an scFv. In one embodiment, the extracellular domain comprises an anti-HLA-A2 antibody of the invention that is an scFab. In one embodiment, the extracellular domain comprises any humanized anti-HLA-A2 antibody of the invention, which is an scFv, scFab, or sdAb. In one embodiment, the extracellular domain comprises any humanized anti-HLA-A2 antibody of the invention, which is an scFv or scFab. In one embodiment, the extracellular domain comprises a humanized anti-HLA-A2 antibody of the invention that is an sdAb. In one embodiment, the extracellular domain comprises a humanized anti-HLA-A2 antibody of the invention that is an scFv. In one embodiment, the extracellular domain comprises a humanized anti-HLA-A2 antibody of the invention that is an scFab.

[0403] In some embodiments, the extracellular domain may comprise a hinge, and the transmembrane domain is attached to the extracellular region of the CAR, e.g., the antigen-binding domain of the CAR, via the hinge. In one embodiment, the hinge may be derived from a human protein. For example, in one embodiment, the hinge may be a human Ig (immunoglobulin) hinge, e.g., an IgG4 hinge, or a CD8α hinge. In some examples, the extracellular domain of a CAR of the invention may comprise a CD8α hinge. In one embodiment, the hinge region comprises the stalk region of CD8α. In one embodiment, the CD8 hinge may be encoded by the nucleic acid sequence of SEQ ID NO: 15 in U.S. Patent No. 9,102,760. In one embodiment, the CD8 hinge may comprise the amino acid sequence of SEQ ID NO: 21 in U.S. Patent No. 9,102,760. In another embodiment, the CD8 hinge may comprise the amino acid sequence of SEQ ID NO: 21 in U.S. Patent No. 9,102,760. In one embodiment, the hinge or spacer may comprise the amino acid sequence of SEQ ID NO: 115 or 219 in Table 3. In one embodiment, the hinge or spacer may be encoded by the nucleic acid sequence of SEQ ID NO: 159 or 220 in Table 4.

[0404] Transmembrane domain

[0405] The transmembrane domain may be derived from either natural or synthetic sources. In one embodiment, the transmembrane domain may be derived from a natural source, such as a membrane-bound protein or a transmembrane protein.

[0406] In one embodiment, the transmembrane domain of the CAR may be derived from a transmembrane domain naturally associated with one of the domains of the CAR, hi other embodiments, the transmembrane domain may be selected or modified by amino acid substitution to avoid binding of the domain to transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.

[0407] In one embodiment, a transmembrane domain may include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acids associated with the extracellular region of the protein from which the transmembrane is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids of the extracellular region) and / or one or more additional amino acids associated with the cytoplasmic region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids of the cytoplasmic region).

[0408] In one embodiment, the transmembrane domain is selected from the group consisting of CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, T cell receptor alpha chain, T cell receptor beta chain, T cell receptor gamma chain, T cell receptor delta chain, CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, KIRDS2, OX40, CD2, CD27, LFA-1 (CD1 la, CD18), ICOS(CD278), 4-1BB(CD137), GITR, CD40, BAFFR, HVEM(LIGHTR), SLAMF7, NKp80(KLRFl), C D160, CD19, IL2R beta, IL2R gamma, IL7Ra, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, IT GAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, PD1, ITGAX, CDl1c, ITGB1, CD29, ITGB2 , CD18, LFA-1, ITGB7, TNFR2, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CDIOO (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / Cbp, NKp44, NKp30, NKp46, NKG2D, and / or NKG2C and CD154, and any combination thereof. In one embodiment, the transmembrane domain may comprise the transmembrane domain of CD28. In one embodiment, the CD28 transmembrane domain is encoded by the nucleic acid sequence of SEQ ID NO: 160 in Table 4. In one embodiment, the CD28 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 116 in Table 3. In another embodiment, the CD28 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 116 in Table 3.

[0409] In one embodiment, the transmembrane domain may comprise the transmembrane domain of CD8. In one embodiment, the CD8 transmembrane domain is encoded by the nucleic acid sequence of SEQ ID NO: 16 of U.S. Patent No. 9,102,760. In one embodiment, the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22 of U.S. Patent No. 9,102,760. In another embodiment, the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22 of U.S. Patent No. 9,102,760.

[0410] In one embodiment, the CD8 transmembrane domain is encoded by the nucleic acid sequence of SEQ ID NO: 224 in Table 4. In one embodiment, the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 223 in Table 3.

[0411] In other embodiments, the transmembrane domain may be synthetic, in which case it may contain predominantly hydrophobic residues including leucine and valine, hi one embodiment, a triplet of phenylalanine, tryptophan and valine is found at each end of the synthetic transmembrane domain.

[0412] In one embodiment, a short oligopeptide or polypeptide linker may form the bond between the transmembrane and cytoplasmic domains of the CAR. In one embodiment, the linker may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length. In one embodiment, the linker may comprise a glycine-serine doublet.

[0413] Cytoplasmic domain

[0414] In one embodiment, the intracellular signaling domain used in the CAR of the invention may include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor binding, as well as derivatives or variants of these sequences, and any synthetic sequences with the same functional capabilities.

[0415] Primary cytoplasmic signaling sequences regulate primary activation of the TCR complex in a stimulatory or inhibitory manner. Stimulatory primary cytoplasmic signaling sequences may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs. Examples of ITAM-containing primary cytoplasmic signaling sequences that are particularly useful in the present invention include those derived from CD3 zeta, FcR gamma, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In one embodiment, the primary signaling domain comprises a modified ITAM domain, e.g., a mutant ITAM domain with altered (e.g., increased or decreased) activity compared to the native ITAM domain. In one embodiment, the primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and / or truncated ITAM-containing primary intracellular signaling domain. In one embodiment, the primary signaling domain comprises one, two, three, four, or more ITAM motifs.

[0416] In one embodiment, the intracellular signaling domain comprises a functional signaling domain of a protein selected from the group consisting of CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, FcR gamma (e.g., FcγRI, RCγRIIA, FcγRIIB1, FcγRIIB2, FcγRIIIA or FcγRIIIB), FcR alpha (e.g., FcαRI), FcR epsilon (e.g., FcεRI or FcεRII), CD5, CD22, CD79a, CD79b, DAP10, DAP12, and CD66d, and any combination thereof. In one embodiment, the intracellular signaling domain comprises or consists of a primary signaling domain of CD3 zeta.

[0417] It is known that signals generated through the TCR alone may be insufficient for full activation of T cells, and that secondary or costimulatory signals may also be required. Thus, in certain embodiments, T cell activation may be mediated by two classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary cytoplasmic signaling sequences) and those that act antigen-independently to provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences). In one embodiment, the intracellular signaling domain may further comprise a costimulatory domain.

[0418] In one embodiment, the intracellular signaling domain of the CAR can comprise a CD3-zeta signaling domain by itself or can be combined with other desired intracellular signaling domain(s) useful in the context of the CAR of the present invention. For example, the intracellular signaling domain of the CAR can comprise a CD3-zeta chain portion and a costimulatory signaling domain. A costimulatory signaling domain refers to a portion of the CAR that includes the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule, other than an antigen receptor or its ligand, that is required for an efficient response of lymphocytes to antigens.Examples of such molecules include OX40, CD27, CD28, lymphocyte function-associated antigen-1 (LFA-1) (CD11a / CD18), TNFR1 (CD120a / TNFRSF1A), TNFR2 (CD120b / TNFRSF1B), CTLA-4 (CD152), CD95, ICOS (CD278), 4-1BB (CD137), CD2, CD30, CD40, PD-1, CD7, LIGHT, NKG2C, B7-H3, ICAM-1, a ligand that specifically binds to CD83, IL2ra (CD25), and I L6Ra (CD126), IL-7Ra (CD127), IL-13RA1, IL-13RA2, IL-33R (IL1RL1), IL-10RA, IL-10RB, IL-4R, IL-5R (CSF2RB), ARHR, BAFF receptor, IL-21R, TGFbR1, TGFbR2, TGFbR3, common gamma chain, MHC class I molecule, BTLA and Toll ligand receptor, ligands that specifically bind to CD83, CDS, ICAM-1, GITR, HVEM (LIGHTR), SLAMF7, NKp8 0(KLRF1), NKp44, NKp30, NKp46, CD160(BY55), CD19, CD19a, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, ITGBD18, ITGBD19 These include 7, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, and NKG2D.

[0419] The intracellular signaling sequences within the cytoplasmic portion of the CAR of the invention may be linked to each other in a random order or a specific order. Optionally, a short oligopeptide or polypeptide linker, e.g., 1 to 10 amino acids in length (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids), may form the linkage between the intracellular signaling sequences. In one embodiment, a glycine-serine doublet may be used as a suitable linker. In one embodiment, a single amino acid, e.g., alanine or glycine, may be used as a suitable linker.

[0420] In one embodiment, the intracellular signaling domain is designed to comprise two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains. In one embodiment, the two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains are separated by a linker molecule, e.g., a linker molecule described herein. In one embodiment, the intracellular signaling domain comprises two costimulatory signaling domains. In some embodiments, the linker molecule is a glycine residue. In some embodiments, the linker is an alanine residue.

[0421] In one embodiment, the cytoplasmic domain may comprise the signaling domain of CD3 zeta and the signaling domain of CD28. In another embodiment, the cytoplasmic domain may comprise the signaling domain of CD3 zeta and the signaling domain of 4-1BB. In yet another embodiment, the cytoplasmic domain may comprise the signaling domain of CD3 zeta and the signaling domains of CD28 and 4-1BB.

[0422] In one embodiment, the cytoplasmic domain may comprise the signaling domain of CD28 and the signaling domain of CD3 zeta, wherein the signaling domain of CD28 is encoded by the nucleic acid sequence set forth in SEQ ID NO: 161 of Table 4, and the signaling domain of CD3 zeta is encoded by the nucleic acid sequence set forth in SEQ ID NO: 162 of Table 4.

[0423] In one embodiment, the cytoplasmic domain may comprise the signaling domain of CD28 and the signaling domain of CD3 zeta, wherein the signaling domain of CD28 comprises the amino acid sequence of SEQ ID NO: 117 in Table 3, and the signaling domain of CD3 zeta comprises the amino acid sequence of SEQ ID NO: 118 in Table 3.

[0424] In one embodiment, the cytoplasmic domain may comprise the signaling domain of CD28 and the signaling domain of CD3 zeta, wherein the signaling domain of CD28 comprises the amino acid sequence set forth in SEQ ID NO: 117 of Table 3, and the signaling domain of CD3 zeta comprises the amino acid sequence set forth in SEQ ID NO: 118 of Table 3.

[0425] In one embodiment, the cytoplasmic domain may comprise the signaling domain of 4-1BB and the signaling domain of CD3 zeta, wherein the signaling domain of 4-1BB is encoded by the nucleic acid sequence set forth in SEQ ID NO: 17 of U.S. Patent No. 9,102,760, and the signaling domain of CD3 zeta is encoded by the nucleic acid sequence set forth in SEQ ID NO: 162 of Table 4.

[0426] In one embodiment, the cytoplasmic domain may comprise the signaling domain of 4-1BB and the signaling domain of CD3 zeta, wherein the signaling domain of 4-1BB comprises the amino acid sequence of SEQ ID NO: 23 of U.S. Patent No. 9,102,760, and the signaling domain of CD3 zeta comprises the amino acid sequence of SEQ ID NO: 118 of Table 3.

[0427] In one embodiment, the cytoplasmic domain may comprise the signaling domain of 4-1BB and the signaling domain of CD3 zeta, wherein the signaling domain of 4-1BB comprises the amino acid sequence set forth in SEQ ID NO: 23 of U.S. Patent No. 9,102,760, and the signaling domain of CD3 zeta comprises the amino acid sequence set forth in SEQ ID NO: 118 of Table 3.

[0428] In one embodiment, the CAR comprises the amino acid sequence set forth in SEQ ID NO: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 or 213. In one embodiment, the CAR comprises an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 or 213.

[0429] V. Nucleic Acids and Vectors

[0430] In some embodiments, the invention provides nucleic acids encoding anti-HLA-A2 antibodies of the invention. In some embodiments, the invention provides nucleic acids encoding humanized anti-HLA-A2 antibodies of the invention. In some embodiments, the invention provides nucleic acids encoding proteins comprising the amino acid sequence set forth in SEQ ID NO: 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or 91. In some embodiments, the invention provides nucleic acids encoding proteins comprising the amino acid sequence set forth in SEQ ID NO: 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, or 112. In some embodiments, the invention provides nucleic acids encoding proteins comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 or 91. In some embodiments, the invention provides nucleic acids encoding proteins comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 93, 94, 95, 96, 97, ... In some embodiments, the invention provides a nucleic acid comprising a nucleic acid sequence set forth in SEQ ID NO: 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, or 158.In some embodiments, the invention provides a nucleic acid comprising a nucleic acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157 or 158. In some embodiments, the invention provides a protein encoded by a nucleic acid comprising a nucleic acid sequence set forth in SEQ ID NO: 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, or 158. In some embodiments, the invention provides a protein encoded by a nucleic acid comprising a nucleic acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, or 158. In some embodiments, the invention provides a nucleic acid encoding a protein comprising an amino acid sequence set forth in SEQ ID NO: 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 71. In some embodiments, the invention provides nucleic acids encoding proteins comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 or 71.

[0431] In some embodiments, the invention provides a nucleic acid encoding a chimeric antigen receptor (CAR) of the invention. The nucleic acid sequence encoding a CAR of the invention may encode a CAR comprising an extracellular domain described anywhere herein.

[0432] The extracellular domain may comprise an anti-HLA-A2 antibody of the present invention. The extracellular domain may comprise a humanized anti-HLA-A2 antibody of the present invention. In one embodiment, the extracellular domain may further comprise a leader sequence. In one embodiment, the leader sequence comprises the amino acid sequence set forth in SEQ ID NO: 113. In one embodiment, the extracellular domain comprises a hinge region, and the anti-HLA-A2 binding domain is linked to the transmembrane domain by the hinge region. In one embodiment, the hinge region comprises the stalk region of CD8α.

[0433] The nucleic acid sequence of the invention may encode a CAR comprising a transmembrane domain as described anywhere herein. For example, in one embodiment, the transmembrane domain is selected from the group consisting of CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, T cell receptor alpha chain, T cell receptor beta chain, T cell receptor gamma chain, T cell receptor delta chain, CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R a, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, PD1, I TGAX, CDl1c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CDIOO (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / CAG, NKp44, NKp30, NKp46, NKG2D and / or NKG2C and CD154, and any combination thereof. In one embodiment, the transmembrane domain comprises the transmembrane domain of CD28.

[0434] The nucleic acid sequences of the present invention may encode a CAR comprising a cytoplasmic domain as described elsewhere herein. Additionally, the cytoplasmic domain may comprise an intracellular signaling domain as described elsewhere herein. For example, in one embodiment, the intracellular signaling domain comprises a functional signaling domain of a protein selected from the group consisting of CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, FcR gamma (e.g., FcγRI, RCγRIIA, FcγRIIB1, FcγRIIB2, FcγRIIIA, or FcγRIIIB), FcR alpha (e.g., FcαRI), FcR epsilon (e.g., FcεRI or FcεRII), CD5, CD22, CD79a, CD79b, DAP10, DAP12, and CD66d, and any combination thereof. In one embodiment, the intracellular signaling domain comprises a functional signaling domain of CD3 zeta. In one embodiment, the intracellular signaling domain further comprises a costimulatory domain. The costimulatory domain of the CAR encoded by the nucleic acid sequence of the invention may be a costimulatory domain described anywhere herein.For example, in one embodiment, the costimulatory domain may be selected from the group consisting of OX40, CD27, CD28, lymphocyte function-associated antigen-1 (LFA-1) (CD11a / CD18), TNFR1 (CD120a / TNFRSF1A), TNFR2 (CD120b / TNFRSF1B), CTLA-4 (CD152), CD95, ICOS (CD278), 4-1BB (CD137), CD2, CD30, CD40, PD-1, CD7, LIGHT, NKG2C, B7-H3, ICAM-1, a ligand that specifically binds to CD83, IL2ra (CD25), IL6Ra (CD126), IL-7Ra (CD127), IL-13RA1, IL-13RA2, IL-33R (IL1RL1), IL-10RA, IL-10RB, IL-4R, IL-5R (CSF2RB), ARHR, BAFF receptor, IL-21R, TGFbR1, TGFbR2, TGFbR3, common gamma chain, MHC class I molecule, BTLA and Toll ligand receptor, ligands that specifically bind to CD83, CDS, ICAM-1, GITR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, N Kp30, NKp46, CD160 (BY55), CD19, CD19a, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CitgbD18, ITGB7, TRANCE / RANKL, DNAM1 (CD226), The present invention includes a functional signaling domain of a protein selected from the group consisting of SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, NKG2D, and any combination thereof.In one embodiment, the costimulatory domain comprises a functional signaling domain of a protein selected from the group consisting of CD28, 4-1BB, and combinations thereof. In one embodiment, the costimulatory domain comprises a functional signaling domain of CD28. In one embodiment, the costimulatory domain comprises a functional signaling domain of 4-1BB. In one embodiment, the sequences comprising the intracellular signaling domain are expressed in the same frame as a single polypeptide chain.

[0435] The nucleic acid sequences of the present invention may be isolated nucleic acid sequences.

[0436] In one embodiment, the nucleic acid is provided as a messenger RNA transcript. In one embodiment, the nucleic acid is provided as a DNA construct.

[0437] In one embodiment, a recombinant DNA construct is provided comprising a sequence encoding a CAR, the CAR comprising (i) an extracellular domain comprising an anti-HLA-A2 antibody, (ii) a transmembrane domain, and (iii) a cytoplasmic domain comprising an intracellular signaling domain, wherein the encoded CAR is capable of being expressed in a human cell such that the CAR can specifically bind to HLA-A2. In one embodiment, the CAR can specifically bind to HLA-A*02:01. In one embodiment, the anti-HLA-A2 antibody is a humanized anti-HLA-A2 antibody. In one embodiment, the human cell is an immune cell. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cell is a regulatory T cell (Treg). In one embodiment, the immune cell is a T cell. In one embodiment, the T cell is a Treg.

[0438] In one embodiment, a recombinant DNA construct is provided comprising a sequence encoding a CAR, the CAR comprising (i) an extracellular domain comprising an anti-HLA-A2 antibody, (ii) a transmembrane domain, and (iii) a cytoplasmic domain comprising an intracellular signaling domain, wherein the encoded CAR is capable of being expressed in regulatory T cells (Tregs) such that the CAR can specifically bind to HLA-A2. In one embodiment, the CAR is capable of specifically binding to HLA-A*02:01. In one embodiment, the binding of the CAR to HLA-A2 can be detected by using an HLA-A2 tetramer as exemplified herein. In one embodiment, the anti-HLA-A2 antibody is a humanized anti-HLA-A2 antibody. In one embodiment, the Tregs are human Tregs.

[0439] In one embodiment, the encoded CAR is capable of being expressed in an immune cell such that the immune cell is activated by HLA-A2. In one embodiment, the immune cell is activated by HLA-A*02:01. In one embodiment, the immune cell is a regulatory immune cell. In one embodiment, the immune cell is a regulatory T cell (Treg). In one embodiment, the immune cell is a T cell. In one embodiment, the T cell is a Treg. In one embodiment, the immune cell is a human immune cell. In one embodiment, the regulatory immune cell is a human regulatory immune cell. In one embodiment, the T cell is a human T cell. In one embodiment, the Treg is a human Treg.

[0440] In one embodiment, the encoded CAR competes for binding to HLA-A2 with an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, the encoded CAR binds to the same HLA-A2 epitope as an antibody comprising a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ ID NO: 183, a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO: 185, a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO: 187, a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO: 188, a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO: 189, and a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO: 190. In one embodiment, the encoded CAR competes with the BB7.2 antibody for binding to HLA-A2. In one embodiment, the encoded CAR binds to the same HLA-A2 epitope as the BB7.2 antibody.

[0441] In some embodiments, the invention provides a nucleic acid encoding a protein comprising the amino acid sequence set forth in SEQ ID NO: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, or 213. In some embodiments, the invention provides nucleic acids encoding proteins comprising an amino acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 or 213. In some embodiments, the invention provides a nucleic acid comprising the nucleic acid sequence set forth in SEQ ID NO: 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, or 214. In some embodiments, the invention provides a nucleic acid comprising a nucleic acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182 or 214. In some embodiments, the invention provides a protein encoded by a nucleic acid comprising the nucleic acid sequence set forth in SEQ ID NO: 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, or 214.In some embodiments, the invention provides a protein encoded by a nucleic acid comprising a nucleic acid sequence having about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, or 214.

[0442] Nucleic acid sequences encoding the desired molecu...

Claims

1. (i) an extracellular domain comprising a humanized anti-HLA-A2 antibody or an antigen-binding fragment thereof, which exhibits reduced binding to one or more HLA-A subtypes selected from one or more of HLA-A*25, HLA-A*29, and HLA-A*30 as compared to the BB7.2 antibody (ATCC deposit no. HB-82); (ii) a transmembrane domain; and (iii) a cytoplasmic domain that includes an intracellular signaling domain; and An expression vector comprising a nucleic acid encoding a chimeric antigen receptor (CAR) comprising: The humanized anti-HLA-A2 antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 61 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 68; (b) a VH comprising the amino acid sequence of SEQ ID NO:64 and a VL comprising the amino acid sequence of SEQ ID NO:68; (c) a VH comprising the amino acid sequence of SEQ ID NO:65 and a VL comprising the amino acid sequence of SEQ ID NO:68; (d) a VH comprising the amino acid sequence of SEQ ID NO: 66 and a VL comprising the amino acid sequence of SEQ ID NO: 68; (e) a VH comprising the amino acid sequence of SEQ ID NO: 64 and a VL comprising the amino acid sequence of SEQ ID NO: 69; (f) a VH comprising the amino acid sequence of SEQ ID NO: 65 and a VL comprising the amino acid sequence of SEQ ID NO: 69; or (g) a VH comprising the amino acid sequence of SEQ ID NO: 63 and a VL comprising the amino acid sequence of SEQ ID NO: 70; Including, the CAR is capable of being expressed in an immune cell such that the CAR specifically binds to HLA-A2; The expression vector is selected from an expression plasmid, a cloning vector, a minicircle, a minivector, a double minute chromosome, a retroviral vector construct, and a lentiviral vector construct. Expression vector.

2. The expression vector described in claim 1, wherein the humanized anti-HLA-A2 antibody or its antigen-binding fragment is an scFv having the amino acid sequence of SEQ ID NO:

73.

3. The CAR, (i) an extracellular domain comprising a humanized anti-HLA-A2 antibody or antigen-binding fragment thereof, wherein the humanized anti-HLA-A2 antibody or antigen-binding fragment thereof is an scFv comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 81, 83, 84, 87, 88, and 91; (ii) the hinge region including the stalk region of CD8α; (iii) the transmembrane domain of CD28; and (iv) an intracellular signaling domain comprising a functional signaling domain of CD3 zeta and a costimulatory domain comprising a functional signaling domain of a protein selected from the group consisting of CD28 and 4-1BB (CD137); The expression vector of claim 1 or 2, comprising:

4. A modified immune cell comprising the expression vector of any one of claims 1 to 3.

5. The modified immune cell of claim 4, further comprising a suicide gene system.

6. The modified immune cell of claim 4 or 5, which is a regulatory T cell (Treg).

7. A pharmaceutical composition comprising an expression vector described in any one of claims 1 to 3 or a plurality of modified immune cells described in any one of claims 4 to 6, and a pharma- ceutically acceptable carrier, diluent or excipient.

8. 8. The pharmaceutical composition of claim 7, for use in promoting immune tolerance in a subject and / or for use in preventing or treating graft-versus-host disease (GVHD) in a subject, wherein the immune tolerance is tolerance to a transplanted organ or tissue.

9. 1 x 10 per kg of body weight 4 ~1×10 9 9. A pharmaceutical composition according to claim 7 or 8, for administration to a subject in a cellular dose.

10. At least 10 4 A pharmaceutical composition according to any one of claims 7 to 9, for administration to a subject in a cellular dose.

11. The pharmaceutical composition according to any one of claims 7 to 10, for administration to a subject in an initial dose and one or more subsequent doses.

12. A pharmaceutical composition described in any one of claims 7 to 11, for administration simultaneously with transplantation of a graft into a subject, prior to transplantation of a graft into a subject, or after transplantation of a graft into a subject.

13. A pharmaceutical composition according to any one of claims 7 to 12, for administration to a subject in combination with another active agent, said another active agent being an immunosuppressant.

14. The pharmaceutical composition according to any one of claims 7 to 13, for administration to a subject prior to, simultaneously with, or after administration of an immunosuppressant.

15. 15. The pharmaceutical composition of claim 13 or 14, wherein the immunosuppressant is selected from the group consisting of calcineurin inhibitors such as cyclosporine, tacrolimus, azathioprine, methotrexate, methoxsalen, rapamycin, mycophenolate mofetil, mycophenolic acid, mycophenolate sodium, 6-mercaptopurine, 6-thioguanine, mTOR inhibitors such as rituximab, sirolimus, everolimus, basiliximab, daclizumab, belatacept, alemtuzumab, muromonab CD3, antithymocyte globulin, glucocorticosteroids, or adrenocorticosteroids such as prednisone or prednisolone, or any combination thereof.

16. A pharmaceutical composition according to any one of claims 7 to 15, for administration to a subject to reduce the amount of an immunosuppressant.

17. A method for producing a modified immune cell according to any one of claims 4 to 6, comprising transducing an immune cell with an expression vector according to any one of claims 1 to 3, thereby generating said modified immune cell.

18. (a) a modified immune cell according to any one of claims 4 to 6; (b) a pharma- ceutically acceptable buffer; and Kit including:

19. 20. The kit of claim 18, further comprising at least one immunosuppressant agent.

Citation Information

Patent Citations

  • JPP7281774B

  • Antibody and functional fragment thereof capable of treating diseases associated with hematopoietic stem cell transplantation such as graft-versus-host disease, and pharmaceutical composition comprising same

    WO2014020922A1